

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 November 2000 (30.11.2000)

PCT

(10) International Publication Number
WO 00/71510 A2

- (51) International Patent Classification⁷: C07C 311/46, C07D 213/74, 295/18, 207/16, 205/04, 207/22, 295/26, 295/22, 233/68, 207/32, 231/12, 217/22, A61K 31/18, 31/33, A61P 7/02
- (21) International Application Number: PCT/US00/14195
- (22) International Filing Date: 24 May 2000 (24.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/135,849 24 May 1999 (24.05.1999) US
- (71) Applicant: COR THERAPEUTICS, INC. [US/US]; 256 E. Grand Avenue, South San Francisco, CA 94080 (US).
- (72) Inventors: SU, Ting; 3222 Upper Lock Avenue, Belmont, CA 94002 (US). ZHU, Bing-Yan; 3325 Adelaide Way, Belmont, CA 94002 (US). KANE-MAGUIRE, Kim; 3425 Lodge Drive, Belmont, CA 94002 (US). SCARBOROUGH, Robert, M.; 22 Greenbrier Court, Half Moon Bay, CA 94019 (US). ZHANG, Penglie; 224 Serrano Drive, South San Francisco, CA 94132 (US).
- (74) Agent: LEE, Christine, S.; Morgan, Lewis & Bockius LLP, 1800 M. Street, N.W., Washington, DC 20036-5869 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/71510 A2

(54) Title: INHIBITORS OF FACTOR Xa

(57) Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful *in vitro* or *in vivo* for preventing or treating coagulation disorders.

- 1 -

INHIBITORS OF FACTOR Xa

Related Applications

- This application claims benefit of priority under 35 USC § 119(e) to U.S.
5 Provisional Application No. 60/135,849 filed on May 24, 1999, which is herein
incorporated in its entirety by reference.

Field of the Invention

This invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa or when assembled in the prothrombinase 10 complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, fIXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin). In another aspect, the present invention relates to novel monoamidino-containing compounds, their pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof which are useful as potent 15 and specific inhibitors of blood coagulation in mammals. In yet another aspect, the invention relates to methods for using these inhibitors as therapeutic agents for disease states in mammals characterized by coagulation disorders.

Background of the Invention

Hemostasis, the control of bleeding, occurs by surgical means, or by the 20 physiological properties of vasoconstriction and coagulation. This invention is particularly concerned with blood coagulation and ways in which it assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Although platelets and 25 blood coagulation are both involved in thrombus formation, certain components of the coagulation cascade are primarily responsible for the amplification or acceleration of the processes involved in platelet aggregation and fibrin deposition.

Thrombin is a key enzyme in the coagulation cascade as well as in hemostasis. Thrombin plays a central role in thrombosis through its ability to catalyze the conversion of fibrinogen into fibrin and through its potent platelet 30 activation activity. Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson, G., "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin

and Other Proteases in the Blood Coagulation System", *Blood Coag. Fibrinol.* 5, 411-436 (1994). Several classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins, heparin-like compounds and coumarins).

5 A prothrombinase complex, including Factor Xa (a serine protease, the activated form of its Factor X precursor and a member of the calcium ion binding, gamma carboxyglutamyl (Gla)-containing, vitamin K dependent, blood coagulation glycoprotein family), converts the zymogen prothrombin into the active 10 procoagulant thrombin. Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin. Since one molecule of factor Xa may be able to generate up to 138 molecules of thrombin (Elodi et al., *Thromb. Res.* 15, 617-619 (1979)), direct inhibition of factor Xa as a way of indirectly inhibiting the formation of thrombin may be an efficient anticoagulant strategy. Therefore, it has 15 been suggested that compounds which selectively inhibit factor Xa may be useful as *in vitro* diagnostic agents, or for therapeutic administration in certain thrombotic disorders, see e.g., WO 94/13693.

Polypeptides derived from hematophagous organisms have been reported 20 which are highly potent and specific inhibitors of factor Xa. United States Patent 4,588,587 describes anticoagulant activity in the saliva of the Mexican leech, *Haementeria officinalis*. A principal component of this saliva was shown to be the polypeptide factor Xa inhibitor, antistasin (ATS), by Nutt, E. et al., "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", *J. Biol. Chem.*, 263, 10162-10167 (1988). Another potent and 25 highly specific inhibitor of Factor Xa, called tick anticoagulant peptide (TAP), has been isolated from the whole body extract of the soft tick *Ornithodoros moubata*, as reported by Waxman, L., et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" *Science*, 248, 593-596 (1990).

Factor Xa inhibitory compounds which are not large polypeptide-type 30 inhibitors have also been reported including: Tidwell, R.R. et al., "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", *Thromb. Res.*, 19, 339-349 (1980); Turner, A.D. et al., "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", *Biochemistry*, 25, 4929-4935 (1986); Hitomi, Y. et al., "Inhibitory Effect of New Synthetic

Protease Inhibitor (FUT-175) on the Coagulation System", *Haemostasis*, 15, 164-168 (1985); Sturzebecher, J. *et al.*, "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", *Thromb. Res.*, 54, 245-252 (1989); Kam, C.M. *et al.*, "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", *Biochemistry*, 27, 2547-2557 (1988); Hauptmann, J. *et al.*, "*Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors*", *Thromb. Haemost.*, 63, 220-223 (1990); and the like.

Others have reported Factor Xa inhibitors which are small molecule organic compounds, such as nitrogen containing heterocyclic compounds which have amidino substituent groups, wherein two functional groups of the compounds can bind to Factor Xa at two of its active sites. For example, WO 98/28269 describes pyrazole compounds having a terminal C(=NH)-NH₂ group; WO 97/21437 describes benzimidazole compounds substituted by a basic radical which are connected to a naphthyl group via a straight or branched chain alkylene,-C(=O) or -S(=O)₂ bridging group; WO 99/10316 describes compounds having a 4-phenyl-N-alkylamidino-piperidine and 4-phenoxy-N-alkylamidino-piperidine group connected to a 3-amidinophenyl group via a carboxamidealkyleneamino bridge; and EP 798295 describes compounds having a 4-phenoxy-N-alkylamidino-piperidine group connected to an amidinonaphthyl group via a substituted or unsubstituted sulfonamide or carboxamide bridging group.

There exists a need for effective therapeutic agents for the regulation of hemostasis, and for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin such as restenosis and inflammation. In particular, there continues to be a need for compounds which selectively inhibit factor Xa or its precursors. Compounds that have different combinations of bridging groups and functional groups than compounds previously discovered are needed, particularly compounds which selectively or preferentially bind to Factor Xa. Compounds with a higher degree of binding to Factor Xa than to thrombin are desired, especially those compounds having good bioavailability and/or solubility.

Summary of the Invention

The present invention relates to novel compounds which inhibit factor Xa,


their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof which have particular biological properties and are useful as potent and specific inhibitors of blood coagulation in mammals. In another aspect, the invention relates to methods 5 of using these inhibitors as diagnostic reagents or as therapeutic agents for disease states in mammals which have coagulation disorders, such as in the treatment or prevention of any thrombotically mediated acute coronary or cerebrovascular syndrome, any thrombotic syndrome occurring in the venous system, any coagulopathy, and any thrombotic complications associated with extracorporeal 10 circulation or instrumentation, and for the inhibition of coagulation in biological samples.

In certain embodiments, this invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus 15 other proteases of the coagulation cascade (e.g. thrombin, etc.) or the fibrinolytic cascade, and are useful as diagnostic reagents as well as antithrombotic agents.

Preferred Embodiments

The invention provides a factor Xa inhibitor compound of the formula:

20



wherein:

A is selected from:

25

- (a) $\text{C}_1\text{-C}_6\text{-alkyl};$
- (b) $\text{C}_3\text{-C}_8\text{-cycloalkyl};$
- (c) $-\text{NR}^2\text{R}^3, -\text{C}(=\text{NR}^2)\text{-NR}^2\text{R}^3, -\text{C}(=\text{NR}^2)\text{-R}^3, -\text{N}(\text{R}^3)\text{-C}(=\text{NR}^2)\text{-NR}^2\text{R}^3;$
- (d) phenyl, which is independently substituted with 0-2 R^1 substituents;
- (e) naphthyl, which is independently substituted with 0-2 R^1 substituents;
- 30 (f) a 3-8 membered saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from

N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system may be substituted with 0-2 R¹ groups;

- 5 (g) a aromatic or non-aromatic fused bicyclic heterocyclic ring system having from 8 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R¹ substituents;

R¹ is selected from:

10 Halo, -C₁₋₄alkyl substituted by up to 4 of the same or different halogen atoms selected independently from the group consisting of chlorine, bromine, iodine and fluorine atoms, -C₁₋₄alkyl, -C₁₋₄alkyl-phenyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, -(CH₂)_mNR²R³, -SO₂NR²R³, -SO₂R², CF₃, -(CH₂)_mOR², -C(=O)-N(R²)R³, -C(=NR²)-NR²R³, -C(=NR²)-R³, -C(=O)-OR², and saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂;

15

20 m is an integer of 0-2;

R² and R³ are each independently selected from the group consisting of:

25 H, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkylphenyl and C₀₋₄alkylnaphthyl, C₀₋₄alkylheterocyclic, wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂, or R² and R³ together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected 30 from the group consisting of O, N and S;

Y is a member selected from the group consisting of:

- 6 -

a direct link; a bivalent C₁-C₄-alkyl group, a bivalent C₂-C₄-alkynyl group, a bivalent C₂-C₄-alkenyl group, -CH₂-, -C(=O)-, -C(=N-R⁴)-, -N(-R⁴)-, -N(-R⁴)-CH₂-, -CH₂-N(-R⁴)-, -C(=O)-N(-R⁴)-, -N(-R⁴)-C(=O)-, -SO₂-, -O-, -SO₂-N(-R⁴)- and -N(-R⁴)-SO₂-;

5 R⁴ is a member selected from the group consisting of:

H, -C₁₋₄-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, -C₀₋₄-alkyl-aryl, -C₀₋₄-alkyl-heterocycle; wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, and -NO₂;

10 D is a direct link or is a member selected from the group consisting of:

- (a) phenyl substituted with 0-2 R^{1a} groups;
- (b) naphthyl substituted with 0-2 R^{1a} groups;
- (c) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

15 R^{1a} is a member selected from the group consisting of:

20 Halo, -C₁₋₄alkyl, -C₁₋₄alkyl-phenyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, -(CH₂)_mNR^{2a}R^{3a}, -SO₂NR^{2a}R^{3a}, -SO₂R^{2a}, CF₃, -(CH₂)_nOR^{2a}, -C(=O)-N(R^{2a})R^{3a}, -C(=NR^{2a})-NR^{2a}R^{3a}, -C(=NR^{2a})-R^{3a}, -C(=O)-OR^{2a}, and saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂;


25 n is an integer of 0-2;

R^{2a} and R^{3a} are each independently selected from the group consisting of:

- 7 -

H, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{0-4} alkylC₃₋₈cycloalkyl, C_{0-4} alkylphenyl and C_{0-4} alkylnaphthyl, C_{0-4} alkylheterocycle, wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, -CN, $-C_{1-4}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-C_{3-8}$ cycloalkyl, $-C_{0-4}$ alkylC₃₋₈cycloalkyl, -N(- C_{1-4} alkyl, $-C_{0-4}$ alkyl), -NH₂, and -NO₂; or R^{2a} and R^{3a} together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

10 E is a member selected from the group consisting of:



R⁵ is a member selected from the group consisting of:

H; $-C_{1-4}$ -alkyl, $-C_{0-4}$ -alkylaryl, $-C_{0-4}$ -alkyl-heteroaryl, and $-C_{1-4}$ -alkyl-C(=O)-O-C₀₋₄-alkyl, $-C_{1-4}$ -alkyl-C(=O)-N(-R^{2b}, -R^{3b});

15 R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H, $-C_{1-4}$ -alkyl, $-C_{0-4}$ -alkyl-aryl, $-C_{0-4}$ -alkyl-heterocycle, and R^{2b} and R^{3b} together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1c} groups;

20 R^{1c} is a member selected from the group consisting of:

Halo, $-C_{1-4}$ -alkyl, -CN, -NO₂, -C(=O)-N(-R^{2c}, -R^{3c}), -C(=O)-OR^{2c}, -(CH₂)₀₋₂-N(-R^{2c}, -R^{3c}), -SO₂-N(-R^{2c}, -R^{3c}), -SO₂R^{2c}, -CF₃ and -(CH₂)₀₋₂-OR^{2c};

R^{2c} and R^{3c} are each independently a member selected from the group consisting of:

H, $-C_{1-4}$ -alkyl, $-C_{0-4}$ -alkyl-aryl, $-C_{0-4}$ -alkyl-heterocyclic group;

25 G is $-CR^6R^{6a}-$, $-CR^6R^{6a}-CR^7R^{7a}-$, $-CR^6R^{6a}-CR^7R^{7a}-CR^{7b}R^{7c}-$,

R⁶, R^{6a}, R⁷, R^{7a}, -R^{7b}, R^{7c} are each a member independently selected from the group consisting of:

- 8 -

- (a) H, alkyl, $-C_{0-2}$ -alkyl-aryl, $-C_{0-2}$ -alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR^9 , -CN, $-CF_3$, $-NO_2$, $-C_{0-2}$ -alkyl-O- C_{2-4} -alkyl-O-R⁹, $-C_{0-2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-C(=O)-OR⁸ and C_{0-2} -alkyl-N(-R⁹, -R¹⁰);
- 5 (b) $-C_{0-2}$ -alkyl-C(=O)-OR⁸, $-C_{0-2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-O-R⁹, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-O-R⁹, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-N(R⁹, R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹)-C(=O)-R¹⁰, $-C_{0-2}$ -alkyl-N(-R⁹)-C(=O)-O-R¹⁰, $-C_{0-2}$ -alkyl-N(-R⁸)-C(=O)-N(-R⁹ -R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹)-SO₂-R¹⁰, $-C_{0-2}$ -alkyl-N(-R₈)-SO₂-N(R⁹, -R¹⁰), and a naturally occurring or synthetic amino acid side chains;

R^8 , R^9 and R^{10} are each a member independently selected from the group consisting of:

H, $-C_{1-4}$ -alkyl, a $-C_{0-4}$ -alkyl-carbocyclic aryl, a $-C_{0-4}$ -alkyl-heterocycle, and

- 15 R^9 with R^{10} , together with the N atom to which they are attached may each independently form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1d} groups;

R^{1d} is a member selected from the group consisting of:

- 20 halo, $-C_{1-4}$ -alkyl, -CN, $-NO_2$, $-C(=O)-N(-R^{2d}, -R^{3d})$, $-C(=O)-OR^{2d}$, $-(CH_2)_m-N(-R^{2d}, -R^{3d})$; $-SO_2-N(-R^{2d}, -R^{3d})$; $-SO_2R^{2d}$; $-CF_3$ and $-(CH_2)_m-OR^{2d}$;

R^{2d} and R^{3d} are each independently a member selected from the group consisting of:

H, $-C_{1-4}$ -alkyl and $-C_{1-4}$ -alkyl-aryl;

J is a member selected from the group consisting of:

- 25 $-O-$, $-O-CH(R^{11})-$, $-S-$, $-S-CH(R^{11})-$, $-S(=O)-$, $-S(=O)_2-$, $-S(=O)-CH(R^{11})-$, $-S(=O)_2-CH(R^{11})-$;

R^{11} is a member selected from the group consisting of:

H, alkyl, $-C_{0.2}$ -alkyl-aryl, $-C_{0.2}$ -alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR^9 , $-CN$, $-CF_3$, $-NO_2$, $-C_{0.2}$ -alkyl-O- $C_{2.4}$ -alkyl-O-R⁹, $-C_{0.2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0.2}$ -alkyl-C(=O)-OR⁸ and $C_{0.2}$ -alkyl-N(-R⁹, -R¹⁰);

5 K is a member selected from the group consisting of:

- (a) phenyl, which is independently substituted with 0-2 R^{1e} groups;
- (b) naphthyl, which is independently substituted with 0-2 R^{1e} groups;
- (c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1e} groups;

R^{1e} is a member independently selected from the group consisting of:

halo, $C_{1.4}$ alkyl, $C_{2.6}$ alkenyl, $C_{2.6}$ alkynyl, $C_{3.8}$ cycloalkyl, $C_{0.4}$ alkylC_{3.8}cycloalkyl, $C_{0.4}$ alkyl aryl, $-C_{0.2}$ -CN, CF_3 , $-C_{0.2}$ -C(=O)-O-R^{2e}, $-C_{0.2}$ -C(=O)-N(-R^{2e}, -R^{3e}), $-C_{0.2}$ -NO₂, $-C_{0.2}$ -N(-R^{2e}, -R^{3e}), $-C_{0.2}$ -SO₂-N(-R^{2e}, -R^{3e}), $-C_{0.2}$ -SO₂-R^{2e}, trihaloalkyl, $-C_{0.2}$ -O-R^{2e}, $C_{0.2}$ -N(-R^{2e})-CH₂-O-R^{2e}, $-O-CH_2-CH_2-O-R^{2e}$, $-O-CH_2-O-R^{2e}$, $-O-CH_2-C(=O)-O-R^{2e}$, $-C_{0.2}$ -N(-R^{2e})-CH₂CH₂-OR^{2e}, $-C_{0.2}$ -N(-R^{2e})-C(=O)-R^{3e}, $-C_{0.2}$ -N(-R^{2e})-SO₂-R^{3e}, $-CH_2-N(-R^{2e})-C(=O)-R^{3e}$ and $-CH_2-N(-R^{2e})-SO_2-R^{3e}$;

20

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

H, $C_{1.4}$ alkyl, $C_{2.6}$ alkenyl, $C_{2.6}$ alkynyl, $C_{3.8}$ cycloalkyl, $C_{0.4}$ alkylC_{3.8}cycloalkyl, $-C_{1.4}$ -alkyl-carbocyclic aryl; $-C_{1.4}$ -alkyl-heterocycle, wherein from 1-4 hydrogen atoms on the ring atoms of aryl moieties may be independently replaced with a member selected from the group consisting of halo, $C_{1.4}$ alkyl, $C_{2.6}$ alkenyl, $C_{2.6}$ alkynyl, $C_{3.8}$ cycloalkyl, $C_{0.4}$ alkylC_{3.8}cycloalkyl, $-CN$ and $-NO_2$, and R^{2e} and R^{3e} together with the N atom to which they are attached can form 5-8 membered heterocyclic ring (substituted with 0-2 R1) containing 1-4 heteroatoms selected from N, O and S which can be substituted with 0-2 R^{1g} groups;

30

R^{1g} is a member selected from the group consisting of:

Halo, -C₁₋₄-alkyl, a carbocyclic aryl group, a saturated, partially unsaturated or aromatic heterocyclic group, -CN, -C(=O)-N(R^{2g})R^{3g}, -C(=O)-OR^{2g}, -NO₂, -(CH₂)_m-NR^{2g}R^{3g}, -SO₂NR^{2g}R^{3g}, -SO₂K^{2g}, -CF₃, and -(CH₂)_mOK^{2g};

5 R^{2g} and R^{3g} are each independently selected from the group consisting of:

H; C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl;

L is selected from:

H, -CN, C(=O)NR¹²R¹³, (CH₂)₀₋₂NR¹²R¹³, C(=NR¹²)NR¹²R¹³, -NR¹²R¹³, OR¹², -NR¹²C(=NR¹²)NR¹²R¹³ and NR¹²C(=NR¹²)-R¹³;

10 R¹² and R¹³ are independently selected from:

hydrogen, -OR¹⁴, -NR¹⁴R¹⁵, C₁₋₄alkyl, C₀₋₄alkylaryl COOC₁₋₄alkyl, and COO-C₀₋₄alkylaryl, OCO-NR¹⁴R¹⁵; OCO-NR¹⁴R¹⁵(CH₂)₀₋₄ NR¹⁴R¹⁵, and R¹² and R¹³ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups 15 consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

R¹⁴ and R¹⁵ are independently selected from:

H, C₁₋₄alkyl; C₀₋₄alkylaryl; C₀₋₄alkylaryl, and R¹⁴ and R¹⁵ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring 20 containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

25 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

In certain aspects of this invention, compounds are provided which are useful as diagnostic reagents. In another aspect, the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the

compounds of this invention and a pharmaceutically acceptable carrier. In yet another aspect, the present invention includes methods comprising using the above compounds and pharmaceutical compositions for preventing or treating disease states characterized by undesired thrombosis or disorders of the blood coagulation process in mammals, or for preventing coagulation in biological samples such as, for example, stored blood products and samples. Optionally, the methods of this invention comprise administering the pharmaceutical composition in combination with an additional therapeutic agent such as an antithrombotic and/or a thrombolytic agent and/or an anticoagulant.

10 The preferred compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.

Detailed Description of the Invention

Definitions

15 In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.

20 The term "alkenyl" refers to a trivalent straight chain or branched chain unsaturated aliphatic radical. The term "alkinyl" (or "alkynyl") refers to a straight or branched chain aliphatic radical that includes at least two carbons joined by a triple bond. If no number of carbons is specified alkenyl and alkinyl each refer to radicals having from 2-12 carbon atoms.

25 The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. The term "cycloalkyl" as used herein refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms.

30 As used herein, the terms "carbocyclic ring structure" and "C₃₋₁₆ carbocyclic mono, bicyclic or tricyclic ring structure" or the like are each intended to mean stable ring structures having only carbon atoms as ring atoms wherein the ring structure is a substituted or unsubstituted member selected from the group consisting of: a stable monocyclic ring which is aromatic ring ("aryl") having six ring atoms;

a stable monocyclic non-aromatic ring having from 3 to 7 ring atoms in the ring; a stable bicyclic ring structure having a total of from 7 to 12 ring atoms in the two rings wherein the bicyclic ring structure is selected from the group consisting of ring structures in which both of the rings are aromatic, ring structures in which one of
5 the rings is aromatic and ring structures in which both of the rings are non-aromatic; and a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein the tricyclic ring structure is selected from the group consisting of: ring structures in which three of the rings are aromatic, ring structures in which two of the rings are aromatic and ring structures in which three of the rings are non-
10 aromatic. In each case, the non-aromatic rings when present in the monocyclic, bicyclic or tricyclic ring structure may independently be saturated, partially saturated or fully saturated. Examples of such carbocyclic ring structures include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane
15 (decalin), 2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any carbon atom which results in a stable structure. The term "substituted" as used in conjunction with carbocyclic ring structures means that hydrogen atoms attached to the ring carbon atoms of ring
20 structures described herein may be substituted by one or more of the substituents indicated for that structure if such substitution(s) would result in a stable compound.

The term "aryl" which is included with the term "carbocyclic ring structure" refers to an unsubstituted or substituted aromatic ring, substituted with one, two or three substituents selected from loweralkoxy, loweralkyl, loweralkylamino,
25 hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide, including but not limited to carbocyclic aryl, heterocyclic aryl, and biaryl groups and the like, all of which may be optionally substituted. Preferred aryl groups include phenyl, halophenyl, loweralkylphenyl, napthyl, biphenyl, phenanthrenyl and naphthacenyl.

30 The term "arylalkyl" which is included with the term "carbocyclic aryl" refers to one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl group having the number of carbon atoms designated. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl,

naphthylmethyl, phenethyl, benzhydryl, trityl, and the like, all of which may be optionally substituted.

As used herein, the term "heterocyclic ring" or "heterocyclic ring system" is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5-7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S; a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two rings wherein at least one of the two rings has from 1 to 4 hetero atoms selected from N, O and S, including bicyclic ring structures wherein any of the described stable monocyclic heterocyclic rings is fused to a hexane or benzene ring; and a stable tricyclic heterocyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein at least one of the three rings has from 1 to 4 hetero atoms selected from the group consisting of N, O and S. Any nitrogen and sulfur atoms present in a heterocyclic ring of such a heterocyclic ring structure may be oxidized.

Unless indicated otherwise the terms "heterocyclic ring" or "heterocyclic ring system" include aromatic rings, as well as non-aromatic rings which can be saturated, partially saturated or fully saturated non-aromatic rings. Also, unless indicated otherwise the term "heterocyclic ring system" includes ring structures wherein all of the rings contain at least one hetero atom as well as structures having less than all of the rings in the ring structure containing at least one hetero atom, for example bicyclic ring structures wherein one ring is a benzene ring and one of the rings has one or more hetero atoms are included within the term "heterocyclic ring systems" as well as bicyclic ring structures wherein each of the two rings has at least one hetero atom. Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any hetero atom or carbon atom which results in a stable structure. Further, the term "substituted" means that one or more of the hydrogen atoms on the ring carbon atom(s) or nitrogen atom(s) of the each of the rings in the ring structures described herein may be replaced by one or more of the indicated substituents if such replacement(s) would result in a stable compound.

Nitrogen atoms in a ring structure may be quaternized, but such compounds are specifically indicated or are included within the term "a pharmaceutically acceptable salt" for a particular compound. When the total number of O and S atoms in a single heterocyclic ring is greater than 1, it is preferred that such atoms not be adjacent to one another. Preferably, there are no more than 1 O or S ring atoms in the same ring of a given heterocyclic ring structure.

Examples of monocyclic and bicyclic heterocyclic ring systems, in alphabetical order, are acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, 5 carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, 10 octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxyathiinyl, phenoxyazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, 15 prydooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuran, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 20 thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl. Preferred heterocyclic ring structures include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocyclic ring structures.

As used herein the term "aromatic heterocyclic ring system" has essentially the same definition as for the monocyclic and bicyclic ring systems except that at least one ring of the ring system is an aromatic heterocyclic ring or the bicyclic ring has an aromatic or non-aromatic heterocyclic ring fused to an aromatic carbocyclic ring structure.

The terms "halo" or "halogen" as used herein refer to Cl, Br, F or I substituents. The term "haloalkyl", and the like, refer to an aliphatic carbon radicals having at least one hydrogen atom replaced by a Cl, Br, F or I atom, including mixtures of different halo atoms. Trihaloalkyl includes trifluoromethyl and the like

as preferred radicals, for example.

The term "methylene" refers to -CH₂-.

The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid.

- 5 These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.

"Pharmaceutically acceptable acid addition salt" refers to salts retaining the biological effectiveness and properties of the free bases and which are not

- 10 biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, 15 ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.

"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.

- Particularly preferred are the ammonium, potassium, sodium, calcium and 20 magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines. Substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, 25 dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.

- 30 "Biological property" for the purposes herein means an *in vivo* effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention that are often shown by *in vitro* assays. Effector functions include

receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or 5 antigenic site that is capable of reacting with antibodies raised against it.

In the compounds of this invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or 10 intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art. Each of the asymmetric carbon atoms, when present in the compounds of this invention, may be in one of 15 two configurations (R or S) and both are within the scope of the present invention.

Preferred Embodiments

The invention provides a factor Xa inhibitor compound of the formula:

20 A-Y-D-E-G-J-Z-L

wherein:

A is selected from:

- 25 (a) C_1-C_6 -alkyl;
- (b) C_3-C_8 -cycloalkyl;
- (c) $-NR^2R^3$, $-C(=NR^2)-NR^2R^3$, $-C(=NR^2)-R^3$, $-N(R^3)-C(=NR^2)-NR^2R^3$;
- (d) phenyl, which is independently substituted with 0-2 R^1 substituents;
- (e) naphthyl, which is independently substituted with 0-2 R^1 substituents;
- 30 (f) a 3-8 membered saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from

N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system may be substituted with 0-2 R¹ groups;

- 5 (g) a aromatic or non-aromatic fused bicyclic heterocyclic ring system having from 8 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R¹ substituents;

R¹ is selected from:

10 Halo, -C₁₋₄alkyl substituted by up to 4 of the same or different halogen atoms selected independently from the group consisting of chlorine, bromine, iodine and fluorine atoms, -C₁₋₄alkyl, -C₁₋₄alkyl-phenyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, -(CH₂)_mNR²R³, -SO₂NR²R³, -SO₂R², CF₃, -(CH₂)_mOR², -C(=O)-N(R²)R³, -C(=NR²)-NR²R³, -C(=NR²)-R³, -C(=O)-OR², and saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂;

15

20 m is an integer of 0-2;

R² and R³ are each independently selected from the group consisting of:

25 H, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkylphenyl and C₀₋₄alkylnaphthyl, C₀₋₄alkylheterocyclic, wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂, or R² and R³ together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

30

Y is a member selected from the group consisting of:

a direct link; a bivalent C₁-C₄-alkyl group, a bivalent C₂-C₄-alkynyl group, a bivalent C₂-C₄-alkenyl group, -CH₂-, -C(=O)-, -C(=N-R⁴)-, -N(-R⁴)-, -N(-R⁴)-CH₂-, -CH₂-N(-R⁴)-, -C(=O)-N(-R⁴)-, -N(-R⁴)-C(=O)-, -SO₂-, -O-, -SO₂-N(-R⁴)- and -N(-R⁴)-SO₂;

5 R⁴ is a member selected from the group consisting of:

H, -C₁₋₄-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, -C₀₋₄-alkyl-aryl; -C₀₋₄-alkyl-heterocycle; wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, and -NO₂;

D is a direct link or is a member selected from the group consisting of:

- (a) phenyl substituted with 0-2 R^{1a} groups;
- (b) naphthyl substituted with 0-2 R^{1a} groups;
- (c) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

R^{1a} is a member selected from the group consisting of:

Halo, -C₁₋₄alkyl, -C₁₋₄alkyl-phenyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, -(CH₂)_mNR^{2a}R^{3a}, -SO₂NR^{2a}R^{3a}, -SO₂R^{2a}, CF₃, -(CH₂)_nOR^{2a}, -C(=O)-N(R^{2a})R^{3a}; -C(=NR^{2a})-NR^{2a}R^{3a}; -C(=NR^{2a})-R^{3a}; -C(=O)-OR^{2a}, and saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂;

n is an integer of 0-2;

R^{2a} and R^{3a} are each independently selected from the group consisting of:

- 19 -

H, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{0-4} alkyl C_{3-8} cycloalkyl, C_{0-4} alkylphenyl and C_{0-4} alkylnaphthyl, C_{0-4} alkylheterocycle, wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, $-CN$, $-C_{1-4}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-C_{3-8}$ cycloalkyl, $-C_{0-4}$ alkyl C_{3-8} cycloalkyl, $-N(-C_{1-4}$ alkyl, $-C_{0-4}$ alkyl), $-NH_2$, and $-NO_2$, or R^{2a} and R^{3a} together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

10 E is a member selected from the group consisting of:

$-C(=O)-N(-R^5)-$, $-N(-R^5)-C(=O)-$, $-N(-R^5)-$, $-N(-R^5)-(CH)_{0-2}-$;

R^5 is a member selected from the group consisting of:

H; $-C_{1-4}$ alkyl, $-C_{0-4}$ alkylaryl, $-C_{0-4}$ alkyl-heteroaryl, and $-C_{1-4}$ alkyl- $C(=O)-O-C_{0-4}$ alkyl, $-C_{1-4}$ alkyl- $C(=O)-N(-R^{2b}, -R^{3b})$;

15 R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H, $-C_{1-4}$ alkyl, $-C_{0-4}$ alkyl-aryl; $-C_{0-4}$ alkyl-heterocycle, and R^{2b} and R^{3b} together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1c} groups;

20 R^{1c} is a member selected from the group consisting of:

Halo, $-C_{1-4}$ alkyl, $-CN$, $-NO_2$, $-C(=O)-N(-R^{2c}, -R^{3c})$, $-C(=O)-OR^{2c}$, $-(CH_2)_{0-2}-N(-R^{2c}, -R^{3c})$, $-SO_2-N(-R^{2c}, -R^{3c})$, $-SO_2R^{2c}$, $-CF_3$ and $-(CH_2)_{0-2}-OR^{2c}$;

R^{2c} and R^{3c} are each independently a member selected from the group consisting of:

H, $-C_{1-4}$ alkyl, $-C_{0-4}$ alkyl-aryl, $-C_{0-4}$ alkyl-heterocyclic group;

25 G is $-CR^6R^{6a}-$, $-CR^6R^{6a}-CR^7R^{7a}-$, $-CR^6R^{6a}-CR^7R^{7a}-CR^{7b}R^{7c}-$,

R^6 , R^{6a} , R^7 , R^{7a} , $-R^{7b}$, R^{7c} are each a member independently selected from the group consisting of:

- 20 -

- (a) H, alkyl, $-C_{0-2}$ -alkyl-aryl, $-C_{0-2}$ -alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR^9 , $-CN$, $-CF_3$, $-NO_2$, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-O-R⁹, $-C_{0-2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-C(=O)-OR⁸ and C₀₋₂-alkyl-N(-R⁹, -R¹⁰);
- 5 (b) $-C_{0-2}$ -alkyl-C(=O)-OR⁸, $-C_{0-2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-O-R⁹, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-O-R⁹, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-N(R⁹, R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹)-C(=O)-R¹⁰, $-C_{0-2}$ -alkyl-N(-R⁹)-C(=O)-O-R¹⁰, $-C_{0-2}$ -alkyl-N(-R⁸)-C(=O)-N(-R⁹ -R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹)-SO₂-R¹⁰, $-C_{0-2}$ -alkyl-N(-R₈)-SO₂-N(R⁹, -R¹⁰), and a naturally occurring or synthetic amino acid side chains;
- 10

R⁸, R⁹ and R¹⁰ are each a member independently selected from the group consisting of:

- H, $-C_{1-4}$ -alkyl, a $-C_{0-4}$ -alkyl-carbocyclic aryl, a $-C_{0-4}$ -alkyl-heterocycle, and
- 15 R⁹ with R¹⁰, together with the N atom to which they are attached may each independently form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1d} groups;

R^{1d} is a member selected from the group consisting of:

- 20 halo, $-C_{1-4}$ -alkyl, $-CN$, $-NO_2$, $-C(=O)-N(-R^{2d}, -R^{3d})$, $-C(=O)-OR^{2d}$, $-(CH_2)_m-N(-R^{2d}, -R^{3d})$; $-SO_2-N(-R^{2d}, -R^{3d})$; $-SO_2R^{2d}$; $-CF_3$ and $-(CH_2)_m-OR^{2d}$;

R^{2d} and R^{3d} are each independently a member selected from the group consisting of:

H, $-C_{1-4}$ -alkyl and $-C_{1-4}$ -alkyl-aryl;

J is a member selected from the group consisting of:

- 25 $-O-$, $-O-CH(R^{11})-$, $-S-$, $-S-CH(R^{11})-$, $-S(=O)-$, $-S(=O)_2-$, $-S(=O)-CH(R^{11})-$, $-S(=O)_2-CH(R^{11})-$;

R¹¹ is a member selected from the group consisting of:

H, alkyl, $-C_{0-2}$ -alkyl-aryl, $-C_{0-2}$ -alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR^9 , $-CN$, $-CF_3$, $-NO_2$, $-C_{0-2}$ -alkyl-O- C_{2-4} -alkyl-O- R^9 , $-C_{0-2}$ -alkyl-C(=O)-N(- R^9 , - R^{10}), $-C_{0-2}$ -alkyl-C(=O)-OR⁸ and C_{0-2} -alkyl-N(- R^9 , - R^{10});

5 K is a member selected from the group consisting of:

- (a) phenyl, which is independently substituted with 0-2 R^{1e} groups;
- (b) naphthyl, which is independently substituted with 0-2 R^{1e} groups;
- (c) a monocyclic or fused bicyclic heterocyclic ring system having from 10 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1e} groups;

R^{1e} is a member independently selected from the group consisting of:

halo, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{0-4} alkylC₃₋₈cycloalkyl, C_{0-4} alkyl aryl, $-C_{0-2}$ -CN, CF_3 , $-C_{0-2}$ -C(=O)-O-R^{2e}, $-C_{0-2}$ -C(=O)-N(-R^{2e}, -R^{3e}), $-C_{0-2}$ -NO₂, $-C_{0-2}$ -N(-R^{2e}, -R^{3e}), $-C_{0-2}$ -SO₂-N(-R^{2e}, -R^{3e}), $-C_{0-2}$ -SO₂-R^{2e}, trihaloalkyl, $-C_{0-2}$ -O-R^{2e}, C_{0-2} -N(-R^{2e})-CH₂-O-R^{2e}, $-O-CH_2-CH_2-O-R^{2e}$, $-O-CH_2-O-R^{2e}$, $-O-CH_2-C(=O)-O-R^{2e}$, $-C_{0-2}-N(-R^{2e})-CH_2CH_2-OR^{2e}$, $-C_{0-2}-N(-R^{2e})-C(=O)-R^{3e}$, $-C_{0-2}-N(-R^{2e})-SO_2-R^{3e}$, $-CH_2-N(-R^{2e})-C(=O)-R^{3e}$ and $-CH_2-N(-R^{2e})-SO_2-R^{3e}$;

20

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

25 H, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{0-4} alkylC₃₋₈cycloalkyl, $-C_{1-4}$ -alkyl-carbocyclic aryl; $-C_{1-4}$ -alkyl-heterocycle, wherein from 1-4 hydrogen atoms on the ring atoms of aryl moieties may be independently replaced with a member selected from the group consisting of halo, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{0-4} alkylC₃₋₈cycloalkyl, -CN and NO_2 , and R^{2e} and R^{3e} together with the N atom to which they are attached can form 5-8 membered heterocyclic ring (substituted with 0-2 R1) containing 1-4 heteroatoms selected from N, O and S which can be substituted with 0-2 R^{1g} groups;

R^{1g} is a member selected from the group consisting of:

Halo, -C₁₋₄-alkyl, a carbocyclic aryl group, a saturated, partially unsaturated or aromatic heterocyclic group, -CN, -C(=O)-N(R^{2g})R^{3g}, -C(=O)-OR^{2g}, -NO₂, -(CH₂)_m-NR^{2g}R^{3g}, -SO₂NR^{2g}R³, -SO₂R^{2g}, -CF₃, and -(CH₂)_mOR^{2g};

5 R^{2g} and R^{3g} are each independently selected from the group consisting of:

H; C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl;

L is selected from:

H, -CN, C(=O)NR¹²R¹³, (CH₂)₀₋₂NR¹²R¹³, C(=NR¹²)NR¹²R¹³, -NR¹²R¹³, OR¹², -NR¹²C(=NR¹²)NR¹²R¹³ and NR¹²C(=NR¹²)-R¹³;

10 R¹² and R¹³ are independently selected from:

hydrogen, -OR¹⁴, -NR¹⁴R¹⁵, C₁₋₄alkyl, C₀₋₄alkylaryl COOC₁₋₄alkyl, and COO-C₀₋₄alkylaryl, OCO-NR¹⁴R¹⁵; OCO-NR¹⁴R¹⁵(CH₂)₀₋₄ NR¹⁴R¹⁵, and R¹² and R¹³ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups 15 consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

R¹⁴ and R¹⁵ are independently selected from:

20 H, C₁₋₄alkyl; C₀₋₄alkylaryl; C₀₋₄alkylaryl, and R¹⁴ and R¹⁵ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

25 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

In a further preferred embodiment the invention provides a factor Xa 30 inhibitor compound of the formula:

A-Y-D-E-G-J-Z-L

wherein:

A is selected from:

- 5 (a) -NR²R³, -C(=NR²)-NR²R³, -C(=NR²)-R³, -N(R³)-C(=NR²)-NR²R³;
- (b) phenyl, which is independently substituted with 0-2 R¹ substituents;
- 10 (C) a 3-7 membered saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system may be substituted with 0-2 R¹ groups;
- (d) a aromatic or non-aromatic fused bicyclic heterocyclic ring system having from 8 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R¹ substituents;

15 R¹ is a member selected from the group consisting of:

halo; C₁₋₄-alkyl, a carbocyclic aryl group, a saturated, partially unsaturated or aromatic heterocyclic group containing 1-4 hetero atoms selected from the group consisting of O, N and S, -CN, -NO₂, -(CH₂)_mNR²R³, -SO₂NR²R³, -SO₂R², CF₃, -(CH₂)_mOR², -C(=O)-N(R²)R³; -C(=NR²)-NR²R³; -C(=NR²)-R³; 20 -C(=O)-OR²;

R² and R³ are each independently selected from the group consisting of:

25 H; -C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl; or R² and R³ together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

m is an integer of 0-2;

Y is a member selected from the group consisting of:

- 24 -

a direct link; $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{N}-\text{R}^4)-$, $-\text{N}(-\text{R}^4)-$, $-\text{N}(-\text{R}^4)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(-\text{R}^4)-$, $-\text{C}(=\text{O})-\text{N}(-\text{R}^4)-$, $-\text{N}(-\text{R}^4)-\text{C}(=\text{O})-$, $-\text{SO}_2-$, $-\text{O}-$, $-\text{SO}_2-\text{N}(-\text{R}^4)-$ and $-\text{N}(-\text{R}^4)-\text{SO}_2-$;

R^4 is a member selected from the group consisting of:

5 H, $-\text{C}_{1-4}\text{-alkyl}$ and $-\text{C}_{0-4}\text{-alkyl-aryl}$;

D is a direct link or is a member selected from the group consisting of:

(a) phenyl substituted with 0-2 R^{1a} groups; and

10 (b) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

R^{1a} is a member selected from the group consisting of:

halo, $-\text{C}_{1-4}\text{-alkyl}$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})-\text{N}(-\text{R}^{2a})$, $-\text{R}^{3a}$, $-\text{C}(=\text{O})-\text{OR}^{2a}$, $-(\text{CH}_2)_m-\text{N}(-\text{R}^{2a}, -\text{R}^{3a})$, $-\text{SO}_2-\text{N}(-\text{R}^{2a}, -\text{R}^{3a})$, $-\text{SO}_2\text{R}^{2a}$, $-\text{CF}_3$ and $-(\text{CH}_2)_m-\text{OR}^{2a}$;

R^{2a} and R^{3a} are each independently a member selected from the group consisting of:

15 H; $-\text{C}_{1-4}\text{-alkyl}$ and $-\text{C}_{1-4}\text{-alkylaryl}$;

E is a member selected from the group consisting of:

$-\text{C}(=\text{O})-\text{N}(-\text{R}^5)-$ and $-\text{N}(-\text{R}^5)-\text{C}(=\text{O})-$;

R^5 is a member selected from the group consisting of:

20 H; $-\text{C}_{1-4}\text{-alkyl}$; $-\text{C}_{0-4}\text{-alkylaryl}$; $-\text{C}_{0-4}\text{-alkyl-heteroaryl}$; $-\text{C}_{1-4}\text{-alkyl-C(=O)-OH}$ and $-\text{C}_{1-4}\text{-alkyl-C(=O)-O-C}_{1-4}\text{-alkyl}$, $-\text{C}_{1-4}\text{-alkyl-C(=O)-N}(-\text{R}^{2b}, -\text{R}^{3b})$;

R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

25 H, $-\text{C}_{1-4}\text{-alkyl}$, $-\text{C}_{0-4}\text{-alkyl-aryl}$; $-\text{C}_{0-4}\text{-alkyl-heterocyclic group}$, and R^{2c} and R^{3b} together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1c} groups;

R^{1c} is a member selected from the group consisting of:

Halo; $-C_{1-4}$ -alkyl; $-CN$, $-NO_2$; $-C(=O)-N(-R^{2c}, -R^{3c})$; $-C(=O)-OR^{2c}$;
 $-(CH_2)_m-N(-R^{2c}, -R^{3c})$; $-SO_2-N(-R^{2c}, -R^{3c})$; $-SO_2R^{2c}$; $-CF_3$ and $-(CH_2)_m-OR^{2c}$;

R^{2c} and R^{3c} are each independently a member selected from the group consisting of:

5 H; $-C_{1-4}$ -alkyl and $-C_{1-4}$ -alkyl-aryl;

G is $-CR^6R^{6a}-$, $-CR^6R^{6a}-CR^7R^{7a}-$,

R^6 , R^{6a} , R^7 , R^{7a} are each a member independently selected from the group consisting of:

10 (a) H, alkyl, $-C_{0-2}$ -alkyl-aryl, $-C_{0-2}$ -alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR^9 , $-CN$, $-CF_3$, $-NO_2$, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-O-R⁹, $-C_{0-2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-C(=O)-OR⁸ and C_{0-2} -alkyl-N(-R⁹, -R¹⁰);

15 (b) $-C_{0-2}$ -alkyl-C(=O)-OR⁸, $-C_{0-2}$ -alkyl-C(=O)-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-O-R⁹, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-O-R⁹, $-C_{0-2}$ -alkyl-O-C₂₋₄-alkyl-N(R⁹, R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹, -R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹)-C(=O)-R¹⁰, $-C_{0-2}$ -alkyl-N(-R⁹)-C(=O)-O-R¹⁰, $-C_{0-2}$ -alkyl-N(-R⁸)-C(=O)-N(-R⁹ -R¹⁰), $-C_{0-2}$ -alkyl-N(-R⁹)-SO₂-R¹⁰, $-C_{0-2}$ -alkyl-N(-R₈)-SO₂-N(R⁹, -R¹⁰), and a naturally occurring or synthetic amino acid side chains;

20 R^8 , R^9 and R^{10} are each a member independently selected from the group consisting of:

H, $-C_{1-4}$ -alkyl, a $-C_{0-4}$ -alkyl-carbocyclic aryl; a $-C_{0-4}$ -alkyl-heterocycle; and

25 R^9 with R^{10} , together with the N atom to which they are attached may each independently form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1d} groups;

R^{1d} is a member selected from the group consisting of:

- 26 -

halo, -C₁₋₄-alkyl, -CN, -NO₂, -C(=O)-N(-R^{2d}, -R^{3d}), -C(=O)-OR^{2d}, -(CH₂)_m-N(-R^{2d}, -R^{3d}); -SO₂-N(-R^{2d}, -R^{3d}); -SO₂R^{2d}; -CF₃ and -(CH₂)_m-OR^{2d};

R^{2d} and R^{3d} are each independently a member selected from the group consisting of:

H, -C₁₋₄-alkyl and -C₁₋₄-alkyl-aryl;

5 J is a member selected from the group consisting of:

-O-, -O-CH(R¹¹)-;

R¹¹ is a member selected from the group consisting of:

H; -C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl;

K is a member selected from the group consisting of:

- 10 (a) phenyl, which is independently substituted with 0-2 R^{1e} groups;
- (b) naphthyl, which is independently substituted with 0-2 R^{1e} groups and
- (c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1e} groups;
- 15

R^{1e} is a member independently selected from the group consisting of:

halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkyl aryl; -C₀₋₂-CN; CF₃, -C₀₋₂-C(=O)-O-R^{2e}; -C₀₋₂-C(=O)-N(-R^{2e}, -R^{3e}); -C₀₋₂-NO₂; -C₀₋₂-N(-R^{2e}, -R^{3e}); -C₀₋₂-SO₂-N(-R^{2e}, -R^{3e}); -C₀₋₂-SO₂-R^{2e}; trihaloalkyl; -C₀₋₂-O-R^{2e}; C₀₋₂-N(-R^{2e})-CH₂-O-R^{2e}; -O-CH₂-CH₂-O-R^{2e} -O-CH₂-O-R^{2e}, -O-CH₂-C(=O)-O-R^{2e}; -C₀₋₂-N(-R^{2e})-CH₂CH₂-OR^{2e}; -C₀₋₂-N(-R^{2e})-C(=O)-R^{3e}; -C₀₋₂-N(-R^{2e})-SO₂-R^{3e}; -CH₂-N(-R^{2e})-C(=O)-R^{3e} and -CH₂-N(-R^{2e})-SO₂-R^{3e};

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

- 25 H, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -C₁₋₄-alkyl-carbocyclic aryl; -C₁₋₄-alkyl-heterocyclic, wherein from 1-4

hydrogen atoms on the ring atoms of aryl moieties may be independently replaced with a member selected from the group consisting of halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN and -NO₂, and R^{2e} and R^{3e} together with the N atom to which they are attached can form 5-8 membered heterocyclic ring (substituted with 0-2 R1) containing 1-4 heteroatoms selected from N, O and S which can be substituted with 0-2 R^{1g} groups;

R^{1g} is a member selected from the group consisting of:

halo; -C₁₋₄-alkyl, a carbocyclic aryl group, a saturated, partially unsaturated or aromatic heterocyclic group, -CN; -C(=O)-N(R^{2g})R^{3g}, -C(=O)-OR^{2g}, -NO₂, -(CH₂)_m-NR^{2g}R^{3g}, -SO₂NR^{2g}R³, -SO₂R^{2g}, -CF₃, and -(CH₂)_mOR^{2g};

R^{2g} and R^{3g} are each independently selected from the group consisting of:

H; C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl;

L is selected from:

H, -CN, C(=O)NR¹²R¹³, (CH₂)_nNR¹²R¹³, C(=NR¹²)NR¹²R¹³, -NR¹²R¹³, OR¹², -NR¹²C(=NR¹²)NR¹²R¹³ and NR¹²C(=NR¹²)-R¹³;

R¹² and R¹³ are independently selected from:

hydrogen, -OR¹⁴, -NR¹⁴R¹⁵, C₁₋₄alkyl, C₀₋₄alkylaryl COOC₁₋₄alkyl, and COO-C₀₋₄alkylaryl, OCO-NR¹⁴R¹⁵, OCO-NR¹⁴R¹⁵(CH₂)₀₋₄NR¹⁴R¹⁵, and R¹² and R¹³ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;


R¹⁴ and R¹⁵ are independently selected from:

H, C₁₋₄alkyl, C₀₋₄alkylaryl, C₀₋₄alkylaryl, and R¹⁴ and R¹⁵ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

C_{1-4} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, -C_{3-8} cycloalkyl, -C_{0-4} alkyl C_{3-8} cycloalkyl, -CN , -NO_2 , and -COO-C_{0-4} alkyl;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

5 In a further preferred embodiment the invention provides a factor Xa inhibitor compound of the formula:



wherein:

10 A is selected from:

- (a) $\text{-NR}^2\text{R}^3$, $\text{-C(=NR}^2\text{)-NR}^2\text{R}^3$, $\text{-C(=NR}^2\text{)-R}^3$, $\text{-N(R}^3\text{)-C(=NR}^2\text{)-NR}^2\text{R}^3$;
- (b) phenyl, which is independently substituted with 0-2 R^1 substituents;
- (c) a 3-7 membered saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system may be substituted with 0-2 R^1 groups;

15 R^1 is a member selected from the group consisting of:

halo; C_{1-4} -alkyl, $\text{-(CH}_2\text{)}_m\text{NR}^2\text{R}^3$, $\text{-SO}_2\text{NR}^2\text{R}^3$, $\text{-SO}_2\text{R}^2$, CF_3 , $\text{-(CH}_2\text{)}_m\text{OR}^2$, $\text{-C(=O)-N(R}^2\text{)R}^3$, $\text{-C(=NR}^2\text{)-NR}^2\text{R}^3$, $\text{-C(=NR}^2\text{)-R}^3$, -C(=O)-OR^2 ;

20 R^2 and R^3 are each independently selected from the group consisting of:

H; -C_{1-4} -alkyl, or R^2 and R^3 together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

m is an integer of 0-2;

25 Y is a member selected from the group consisting of:

a direct link, $\text{-CH}_2\text{-}$, -C(=O)- , $\text{-C(=N-R}^4\text{)-}$, $\text{-N(-R}^4\text{)-}$, $\text{-N(-R}^4\text{)-CH}_2\text{-}$, and $\text{-SO}_2\text{-}$;

R^4 is a member selected from the group consisting of:

H, -C₁₋₄-alkyl;

D is a direct link or is a member selected from the group consisting of:

- (a) phenyl substituted with 0-2 R^{1a} groups; and
- 5 (b) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

R^{1a} is a member selected from the group consisting of:

halo, -C₁₋₄-alkyl;

E is a member selected from the group consisting of:

10 -N(-R⁵)-C(=O)-;

R⁵ is a member selected from the group consisting of:

H; -C₁₋₄-alkyl, -C₀₋₄-alkylaryl, -C₀₋₄-alkyl-heteroaryl, -C₁₋₄-alkyl-C(=O)-OH and -C₁₋₄-alkyl-C(=O)-O-C₁₋₄-alkyl, -C₁₋₄-alkyl-C(=O)-N(-R^{2b}, -R^{3b});

R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

15 H, -C₁₋₄-alkyl;

G is -CR⁶R^{6a}-, -CR⁶R^{6a}-CR⁷R^{7a}-,

R⁶, R^{6a}, R⁷, R^{7a} are each a member independently selected from the group consisting of:

20 H, alkyl, -C₀₋₂-alkyl-aryl, -C₀₋₂-alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR⁹, -CN, -CF₃, -NO₂, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-O-R⁹, -C₀₋₂-alkyl-C(=O)-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-C(=O)-OR⁸ and C₀₋₂-alkyl-N(-R⁹, -R¹⁰);

25 R⁸, R⁹ and R¹⁰ are each a member independently selected from the group consisting of:

H, -C₁₋₄-alkyl;

J is a member selected from the group consisting of:

-O-;

K is a member selected from the group consisting of:

- (a) phenyl, which is independently substituted with 0-2 R^{1e} groups;
- 5 (b) naphthyl, which is independently substituted with 0-2 R^{1e} groups and
- (c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1e} groups;

10 R^{1e} is a member independently selected from the group consisting of:

halo, C₁₋₄alkyl, -C₀₋₂-N(-R^{2e}, -R^{3e}), -C₀₋₂-O-R^{2e}, C₀₋₂-N(-R^{2e})-CH₂-O-R^{2e},
 -O-CH₂-CH₂-O-R^{2e}, -O-CH₂-O-R^{2e}, -O-CH₂-C(=O)-O-R^{2e},
 -C₀₋₂-N(-R^{2e})-CH₂CH₂-OR^{2e}

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

15 H, C₁₋₄alkyl;

L is selected from:

(CH₂)₀₋₂NR¹²R¹³, C(=NR¹²)NR¹²R¹³, -NR¹²C(=NR¹²)NR¹²R¹³;

R¹² and R¹³ are independently selected from:

- hydrogen, -OR¹⁴, -NR¹⁴R¹⁵, C₁₋₄alkyl, COOC₁₋₄alkyl, and COO-C₀₋₄alkylaryl,
 20 OCO-NR¹⁴R¹⁵; OCO-NR¹⁴R¹⁵(CH₂)₀₋₄NR¹⁴R¹⁵, and R¹² and R¹³ together with
 the N atom to which they are attached can form a 5-8 membered heterocyclic
 ring containing 1-4 heteroatoms selected from N, O and S, wherein the
 heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl,
 -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -
 25 CN, -NO₂, and -COO-C₀₋₄alkyl;

R¹⁴ and R¹⁵ are independently selected from:

H, C₁₋₄alkyl;

- 31 -

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.


In a more preferred embodiment the invention provides a factor Xa inhibitor compound of the formula:

5

A-Y-D-E-G-J-Z-L

Wherein:

A is a member selected from the group consisting of:




Y is a member selected from the group consisting of:

- 33 -

a direct link, -CH₂-, -C(=O)-, -NH-, -N(-CH₃)-, -N(-CH₃)-CH₂-, -C(=NH)- and -SO₂-

D is a member selected from the group consisting of:

5



E is a member selected from the group consisting of:

-N(-R⁵)-C(=O)-;

R⁵ is a member selected from the group consisting of:

10 H; -C₁₋₄-alkyl; -C₀₋₄-alkylaryl; -C₀₋₄-alkyl-heteroaryl; -C₁₋₄-alkyl-C(=O)-OH and -C₁₋₄-alkyl-C(=O)-O-C₁₋₄-alkyl, -C₁₋₄-alkyl-C(=O)-N(-R^{2b}, -R^{3b});

R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H, -C₁₋₄-alkyl;

G is -CR⁶R^{6a}-, -CR⁶R^{6a}-CR⁷R^{7a}-,


15

R^6 , R^{6a} , R^7 , R^{7a} are each a member independently selected from the group consisting of:

H, alkyl, $-C_{0-2}$ -alkyl-aryl, $-C_{0-2}$ -alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo; -CN; $-CF_3$; $-NO_2$; $-C_{0-2}$ -alkyl-C(=O)-NH₂; $-C_{0-2}$ -alkyl-C(=O)-OH; and C_{0-2} -alkyl-NH₂; C_{0-2} -alkyl-OH; C_{0-2} -alkyl-OMe;


5 J is -O-;

K and L taken together are a member selected from the group consisting of:




and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

In another preferred embodiment, the present invention provides a
5 compound of the following formulae:



wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:




Y is a member selected from the group consisting of:

- 5 a direct link, -CH₂-, -C(=O)-, -NH-, -N(-CH₃)-, -N(-CH₃)-CH₂-, -C(=NH)- and -SO₂-


R^{1a} is selected from the group consisting of:

-H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂;
-C(=O)-O-Me;

In another preferred embodiment the present invention provides a compound
5 having one of the following formulae:



wherein the A portion for each of the above formulae is independently a member
10 selected from the group consisting of:




Y is a member selected from the group consisting of:

- 5 a direct link, $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{NH}-$, $-\text{N}(-\text{CH}_3)-$, $-\text{N}(-\text{CH}_3)\text{-CH}_2-$, $-\text{C}(=\text{NH})-$ and $-\text{SO}_2-$


R^{1a} is selected from the group consisting of:

-H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂;
-C(=O)-O-Me;

- 5 In another preferred embodiment the present invention provides a compound having one of the following formula



- 10 wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:




Y is a member selected from the group consisting of:

- 5 a direct link, $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{NH}-$, $-\text{N}(-\text{CH}_3)-$, $-\text{N}(-\text{CH}_3)\text{-CH}_2-$, $-\text{C}(=\text{NH})-$ and $-\text{SO}_2-$


R^{1a} is selected from the group consisting of:

-H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂;
-C(=O)-O-Me;

- 5 In another preferred embodiment the present invention provides a compound having one of the following formula



- 10 wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:





Y is a member selected from the group consisting of:

- 5 a direct link, $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{NH}-$, $-\text{N}(-\text{CH}_3)-$, $-\text{N}(-\text{CH}_3)\text{-CH}_2-$, $-\text{C}(=\text{NH})-$ and $-\text{SO}_2-$

R^{1a} is selected from the group consisting of:


-H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂;
-C(=O)-O-Me;

- 5 In another preferred embodiment the present invention provides a compound having one of the following formula




10

wherein the D portion for each of the above formulae is independently a member selected from the group consisting of:



5

In another preferred embodiment the present invention provides a compound having one of the following formula:



10


wherein the D portion for each of the above formulae is independently a member selected from the group consisting of:

15

- 45 -

In another preferred embodiment the present invention provides a compound having one of the following formula:

5




wherein

10 R^{1b} is each a member independently selected from the group consisting of:

H, Br, F, Cl, I, NH₂, OH, OMe, -CN, -CF₃, -NO₂, -CO₂H, CO₂Me;


In another preferred embodiment the present invention provides a compound having one of the following formula:

15





wherein the Z-L portion for each of the above formulae is independently a member selected from the group consisting of:


20





The following non-limiting examples illustrate representative compounds of the present invention:











This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates and solvates of the compounds of formulas I, II and III. In addition, the compounds of formulas I, II and III can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates and solvates of such isomers and

tautomers.

The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts
5 are particularly useful although other less desirable salts may have use in the processes of isolation and purification.

A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulas above can be reacted with one or
10 more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the
15 same general process.

Prodrug Derivatives of Compounds

This invention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either
20 spontaneous or enzymatic, within the organism to release the active drug. Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active *in vivo*, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug
25 compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp.
30 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992). Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the

parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative. Moreover, the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.

5 As mentioned above, the compounds of this invention find utility as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic
10 shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. Further, these compounds are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex. This includes a number of thrombotic and prothrombotic states in which the coagulation
15 cascade is activated which include but are not limited to, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion.

Accordingly, a method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprises administering to the mammal a therapeutically effective amount of a compound of this invention. In addition to the disease states noted above, other diseases treatable or preventable by the administration of compounds of this invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.

30 The compounds of the invention also find utility in a method for inhibiting the coagulation biological samples, which comprises the administration of a compound of the invention.

The compounds of the present invention may also be used in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals such as primates, (e.g. humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the *in vitro* protease activity assays and *in vivo* studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.

Diagnostic applications of the compounds of this invention will typically utilize formulations in the form of solutions or suspensions. In the management of thrombotic disorders the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.

Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents

for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate 5 and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including 10 cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.

Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by 15 filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be 3-11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the 20 formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as orally, intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally, transdermally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral 25 dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.

30 The compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds of this invention may also be delivered by the use of

antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidinone, pyran copolymer, polyhydroxy-
5 propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon-
10 caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.

Therapeutic compound liquid formulations generally are placed into a
15 container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.

Therapeutically effective dosages may be determined by either *in vitro* or *in vivo* methods. For each particular compound of the present invention, individual
20 determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will be influenced by the route of administration, the therapeutic objectives and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be
25 individually determined for each compound by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in
30 the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.

The compounds of the invention can be administered orally or parenterally in an effective amount within the dosage range of about 0.1 to 100 mg/kg,
35 preferably about 0.5 to 50 mg/kg and more preferably about 1 to 20 mg/kg on a

regimen in a single or 2 to 4 divided daily doses and/or continuous infusion.

Typically, about 5 to 500 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice. The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.

Typical adjuvants which may be incorporated into tablets, capsules and the like are binders such as acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents. When a dosage form is a capsule, in addition to the above materials it may also contain liquid carriers such as water, saline, or a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.

Preparation of Compounds

The compounds of the present invention may be synthesized by either solid or liquid phase methods described and referenced in standard textbooks, or by a combination of both methods. These methods are well known in the art. See, Bodanszky, "The Principles of Peptide Synthesis", Hafner, *et al.*, Eds., Springer-Verlag, Berlin, 1984.

Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.

Reactions are carried out in standard laboratory glassware and reaction

vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.


During the synthesis of these compounds, the functional groups of the amino acid derivatives used in these methods are protected by blocking groups to prevent cross reaction during the coupling procedure. Examples of suitable blocking groups and their use are described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol. 3 (Gross, *et al.*, Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference.

10


Non-limiting exemplary synthesis schemes are outlined directly below, and specific steps are described in the Examples. The reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent. The products may be further purified by column chromatography or other appropriate methods.

15


- 59 -

Scheme 1

- 60 -

Scheme 2


- 61 -

Scheme 3


5

10


- 62 -

Scheme 4


5

Scheme 5

- 63 -


Scheme 6

5


Scheme 7

10

- 64 -

Scheme 8


5

Scheme 9

10

- 65 -

Scheme 10



Compositions and Formulations

5 The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.

10 A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, reaction of the free acid or free base form of a compound of the structures recited above with one or

more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the
5 desired salt or one salt form of the product may be converted to another using the same general process.

Diagnostic applications of the compounds of this invention will typically utilize formulations such as solution or suspension. In the management of thrombotic disorders the compounds of this invention may be utilized in
10 compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary
15 from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.

Formulations of the compounds of this invention are prepared for storage or
20 administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., (A.R.
25 Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate

and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.

Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8.

It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example. Silastic, silicone rubber or other polymers commercially available.

The compounds of this invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.

5 The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-
10 propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the factor Xa inhibitors of this invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon-
15 caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.

20 Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.

25 Therapeutically effective dosages may be determined by either *in vitro* or *in vivo* methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives, and the condition of the patient. For

injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each inhibitor by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the
5 route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.

10 A typical dosage might range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg, and more preferably from about 0.10 mg/kg to about 20 mg/kg. Advantageously, the compounds of this invention may be administered several times daily, and other dosage regimens may also be useful.

15 Typically, about 0.5 to 500 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice. The amount of active ingredient in these compositions is such that a
20 suitable dosage in the range indicated is obtained.

Typical adjuvants which may be incorporated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and excipient such as microcrystalline cellulose, a disintegrating agent like corn starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose,
25 or a flavoring agent. When a dosage form is a capsule, in addition to the above

materials it may also contain a liquid carrier such as water, saline, a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice, such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals such as primates, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

The preferred compounds of the present invention are characterized by their ability to inhibit thrombus formation with acceptable effects on classical measures of coagulation parameters, platelets and platelet function, and acceptable levels of bleeding complications associated with their use. Conditions characterized by undesired thrombosis would include those involving the arterial and venous vasculature.

With respect to the coronary arterial vasculature, abnormal thrombus formation characterizes the rupture of an established atherosclerotic plaque which is

the major cause of acute myocardial infarction and unstable angina, as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA).

With respect to the venous vasculature, abnormal thrombus formation
5 characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism. Abnormal thrombus formation further characterizes disseminated intravascular coagulopathy commonly occurs within both
10 vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.

The compounds of this present invention, selected and used as disclosed
15 herein, are believed to be useful for preventing or treating a condition characterized by undesired thrombosis, such as (a) the treatment or prevention of any thrombotically mediated acute coronary syndrome including myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, (b) the treatment or prevention of any thrombotically mediated cerebrovascular syndrome including embolic stroke, thrombotic stroke or transient ischemic attacks, (c) the treatment or prevention of any thrombotic syndrome occurring in the venous system including deep venous thrombosis or pulmonary embolus occurring either spontaneously or in the setting of malignancy, surgery or trauma, (d) the treatment or prevention of any coagulopathy including disseminated intravascular coagulation (including the setting of septic shock or other infection, surgery, pregnancy, trauma or malignancy and whether
20
25

associated with multi-organ failure or not), thrombotic thrombocytopenic purpura, thromboangiitis obliterans, or thrombotic disease associated with heparin induced thrombocytopenia, (e) the treatment or prevention of thrombotic complications associated with extracorporeal circulation (e.g. renal dialysis, cardiopulmonary bypass or other oxygenation procedure, plasmapheresis), (f) the treatment or prevention of thrombotic complications associated with instrumentation (e.g. cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve), and (g) those involved with the fitting of prosthetic devices.

Anticoagulant therapy is also useful to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus the compounds of this invention can be added to or contacted with any medium containing or suspected to contain factor Xa and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material such as vascular grafts, stents, orthopedic prostheses, cardiac stents, valves and prostheses, extra corporeal circulation systems and the like.


Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

EXAMPLE S

Example 1

Preparation of 3-(*{N*-[4-(2-sulfamoylphenyl)phenyl]carbamoyl}methoxy)benzenecarboxamidine


5



A. Preparation of 2-(3-cyanophenoxy)acetic acid

To a solution of t-butyl bromoacetate (1.62 mL, 10 mmol), 3-cyanophenol (1.19 g, 10 mmol), potassium carbonate (2.76 g, 20 mmol) in CH₃CN (15 mL) and acetone (5 mL), was added KI (165 mg, 1 mmol). The mixture was heated to reflux for 2 hrs. The mixture was cooled to room temperature and solvent was removed *in vacuo*. Ether and water were added to the mixture and organic layer was washed with 2N NaOH, brine, dried over Na₂SO₄, filtered and the filtrated were concentrated in vacuo to give the title compound (2.53 g, 100%). ES-MS (M+H)⁺ = 234.1


B. Preparation of (tert-butyl)(phenylsulfonyl)amine



20

To a solution of tert-Butylamine (41.4g, 566 mmol) and triethylamine (118 mL, 849 mmol) in DCM (1000 mL) in an ice bath, was added benzenesulfonyl chloride (100 g, 566 mmol) dropwise. The mixture was stirred at room temperature overnight. Water was added to the mixture and organic layer was washed with water, brine, dried over Na₂SO₄, filtered and filtrated evaporated *in vacuo* to give the title compound as light yellowish solid (117.63 g, 97.6%). ES-MS (M+H)⁺ = 214.1.

C. Preparation of 2-[(tert-butyl amino)sulfonyl]phenyl boronic acid




5

To a solution of compound of B (53.25 g, 250 mmol) in THF (600 mL) in an ice bath, was added n-butyllithium in hexane (200 mL, 500 mmol) dropwise. A thick precipitate was formed when the reaction mixture was warmed up to 10°C.

Triisopropylborate was added keeping the temperature below 35°C. After 1 hr., the 10 mixture was cooled in an ice bath, 1N HCl (405 mL) was added, and the mixture was stirred overnight. The mixture was extracted with ether (100 mL) three times. The combined organic extracts were extracted with 1N NaOH (130 mL) three times. The aqueous extracts were acidified to pH 1 with 12 N HCl, and then extracted with ether three times (140 mL). The combined ether extracts were dried over MgSO₄, 15 and solvents evaporated *in vacuo*. Hexane and ether were added and a white precipitate was formed. The solid was collected and washed with 10% ether/hexane to give the title compound. ES-MS (M+H)⁺ = 258.1.


D. Preparation of {[2-(4-aminophenyl)phenyl]sulfonyl}(tert-butyl)amine

20



To a solution of compound of C (6.4 g, 25 mmol) in toluene (120 mL) was 25 added water (15 mL), 5N NaOH solution (38.5 mL), isopropanol (60 mL), 4-bromoaniline and tetrakis(triphenylphosphine)palladium(0). The mixture was refluxed for six hours, cooled to room temperature, diluted with EtOAc. The organic layer was washed with water, dried with MgSO₄, filtered and concentrated. This was purified by silica gel column chromatography using solvent system 30% EtOAc in hexane as eluant to give the title compound (5g, 66%). ES-MS M+H = 305.1.

E. Preparation of




5 The compound of A (0.3 mmol) was treated with 50% TFA in DCM (4 mL).
The mixture was stirred at room temperature for 30 minutes and solvent evaporated
to give a white solid. This was dissolved in DMF (2 mL) and cooled to 0°C. The
solution was neutralized with DIEA (87 µL, 0.5 mmol) followed by the addition of
compound of example 4 (76 mg, 0.25 mmol) and coupling reagent BOP(132.8 mg,
10 0.3 mmol). The solution was stirred at room temperature for 15 hours. The reaction
mixture was diluted in a mixture of EtOAc/H₂O (10 mL:5mL). The organic layer
was washed with sat. NaHCO₃ (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over
MgSO₄, filtered and solvent evaporated to give the crude product. This was purified
by silica gel column chromatography using solvent system 50% EtOAc in hexane as
15 eluant to give the title compound (121 mg, 100%). ES-MS (M+Na)⁺ = 486.15.

F. Preparation of 3-(N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl)methoxybenzenecarboxamidine


20 A solution of the compound E (121 mg, 0.26 mmol), hydroxylamine
hydrochloride (36.14 mg, 0.52 mmol), TEA (109 µL, 0.78 mmol) in absolute
ethanol (4 mL) was heated up to 60°C and stirred for 15 hrs. The solution was
cooled and solvent evaporated. The residue was dissolved in AcOH (2 mL). Ac₂O
25 (98.5 µL, 1.04 mmol) was added. The mixture was stirred at room temperature for
50 min. and the solvent evaporated. The residue was dissolved in MeOH (2-3 mL)
and 10% Pd/C (catalytic amount) was added. The mixture was hydrogenated under
balloon overnight, filtered through Celite to remove the catalyst and the filtrate was
evaporated. TFA (2-3 mL) was added to the residue and the mixture was stirred at
30 room temperature for 2-3 hrs. TFA was removed under reduced pressure to give the
crude product. The obtained residue was purified by RP-HPLC to give the title
compound as a white powder. ES-MS (M+H)⁺ = 425.1.

Example 2 Preparation of 7-(*{N*-[4-(2-sulfamoylphenyl)phenyl]carbamoyl}methoxy)naphthalene-2-carboxamidine

5




A. Preparation of



To a solution of t-butyl bromoacetate (1.62 mL, 10 mmol), 7-cyano-2-naphthol (1.69 g, 10 mmol), potassium carbonate (2.76 g, 20 mmol) in CH₃CN (15 mL) and acetone (5 mL), was added KI (165 mg, 1 mmol). The mixture was heated to reflux for 2 hrs. The mixture was cooled to room temperature and solvent was removed *in vacuo*. Ether and water were added to the mixture and organic layer was washed with 2N NaOH, brine, dried over Na₂SO₄, filtered and the filtrated were concentrated *in vacuo* to give the title compound (2.76 g, 97.5%). ES-MS (M+H)⁺ = 284.1.

B. Preparation of



20

The compound of A (0.3 mmol) was treated with 50% TFA in DCM (4 mL). The mixture was stirred at room temperature for 30 minutes and solvent evaporated to give a white solid. This was dissolved in DMF (2 mL) and cooled to 0°C. The solution was neutralized with DIEA (87 µL, 0.5 mmol) followed by the addition of compound of D in example 1(76 mg, 0.25 mmol) and coupling reagent BOP(132.8 mg, 0.3 mmol). The solution was stirred at room temperature for 15 hours. The reaction mixture was diluted in a mixture of EtOAc/H₂O (10 mL:5mL). The

- 77 -

organic layer was washed with sat. NaHCO₃ (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO₄, filtered and solvent evaporated to give the crude product. This was purified by silica gel column chromatography using solvent system 50% EtOAc in hexane as eluant to give the title compound (142 mg, 92.2%). ES-MS (M+Na)⁺ = 536.15.

5 C. Preparation of 7-(N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl)methoxy)naphthalene-2-carboxamidine


10 A solution of the compound of B (142 mg, 0.28 mmol), hydroxylamine hydrochloride (38.5 mg, 0.55 mmol), TEA (115 µL, 0.83 mmol) in absolute ethanol (4 mL) was heated up to 60°C and stirred for 15 hrs. The solution was cooled and solvent evaporated. The residue was dissolved in AcOH (2 mL). Ac₂O (104 µL, 1.11 mmol) was added. The mixture was stirred at room temperature for 50 min.

15 and the solvent evaporated. The residue was dissolved in MeOH (2-3 mL) and 10% Pd/C (catalytic amount) was added. The mixture was hydrogenated under balloon overnight, filtered through Celite to remove the catalyst and the filtrate was evaporated. TFA (2-3 mL) was added to the residue and the mixture was stirred at room temperature for 2-3 hrs. TFA was removed under reduced pressure to give the


20 crude product. The obtained residue was purified by RP-HPLC to give the title compound as a white powder. ES-MS (M+H)⁺ = 475.1.

Example 3 Preparation of 3-[2-oxo-1-phenyl-2-(4-(4-pyridyl)piperazinyl)ethoxy]benzenecarboxamidine

25



30 A. Preparation of




The compound of A in example 1 (1 mmol) was treated with 50% TFA in DCM (4 mL). The mixture was stirred at room temperature for 30 minutes and solvent evaporated to give a white solid. This was dissolved in DMF (8 mL) and cooled to 0°C. The solution was neutralized with DIEA (349 µL, 2 mmol) followed by the addition of 1-(4-pyridyl)-piperazine (194 mg, 1.2 mmol) and coupling reagent BOP (531 mg, 1.2 mmol). The solution was stirred at room temperature for 15 hours. The reaction mixture was diluted in a mixture of EtOAc/H₂O (10 mL:5mL). The organic layer was washed with sat. NaHCO₃ (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO₄, filtered and solvent evaporated to give the title compound (132 mg, 41%). ES-MS (M+H)⁺ = 322.1.

B. Preparation of 3-[2-oxo-1-phenyl-2-(4-(4-pyridyl)piperazinyl)ethoxy]benzenecarboxamidine

A solution of the compound of A (132 mg, 0.41 mmol) in MeOH (3 mL) was treated with a stream of HCl gas for 10 min. at 0°C. The resulting solution was capped, stirred at room temperature overnight and evaporated *in vacuo*. The residue was reconstituted in MeOH (3 mL) and the mixture was treated with NH₄OAc (142.6 mg, 1.85 mmol). The reaction mixture was refluxed for 1.5 hrs. and concentrated *in vacuo*. The obtained residue was purified by RP-HPLC to give the title compound as a white powder. ES-MS (M+H)⁺ = 340.1.


Example 4 Preparation of 7-[2-oxo-1-phenyl-2-(4-(4-pyridyl)piperazinyl)ethoxy]naphthalene-2-carboxamidine



25

A. Preparation of

30




The compound of A in example 2 (1 mmol) was treated with 50% TFA in DCM (4 mL). The mixture was stirred at room temperature for 30 minutes and solvent evaporated to give a white solid. This was dissolved in DMF (8 mL) and cooled to 0°C. The solution was neutralized with DIEA (349 µL, 2 mmol) followed by the addition of 1-(4-pyridyl)-piperazine (194 mg, 1.2 mmol) and coupling reagent BOP(531 mg, 1.2 mmol). The solution was stirred at room temperature for 15 hours. The reaction mixture was diluted in a mixture of EtOAc/H₂O (10 mL:5mL). The organic layer was washed with sat. NaHCO₃ (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO₄, filtered and solvent evaporated to give the title compound (209 mg, 56.3%). ES-MS (M+H)⁺ = 372.1.

B. Preparation of 7-[2-oxo-1-phenyl-2-(4-(4-pyridyl)piperazinyl)ethoxy]naphthalene-2-carboxamidine

A solution of the compound of A (113 mg, 0.3 mmol) in MeOH (3 mL) was treated with a stream of HCl gas for 10 min. at 0°C. The resulting solution was capped, stirred at room temperature overnight and evaporated *in vacuo*. The residue was reconstituted in MeOH (3 mL) and the mixture was treated with NH₄OAc (115.6 mg, 1.5 mmol). The reaction mixture was refluxed for 1.5 hrs. and concentrated *in vacuo*. The obtained residue was purified by RP-HPLC to give the title compound as a white powder. ES-MS (M+H)⁺ = 390.1.

Example 5 Preparation of 3-(N-[4-(pyrrolidinylcarbonyl)phenyl]carbamoyl)methoxybenzenecarboxamidine



A. Preparation of 2-(3-cyanophenoxy)acetic acid

To a chilled solution of 3-cyanophenol (0.18 g, 1.5 mmol) in DMF (2 mL) was added solid cesium carbonate (1.22 g, 3.74 mmol), followed by t-butyl

bromoacetate (0.24 mL, 1.63 mmol) via pipet. The reaction mixture was stirred vigorously at room temperature for 1.5 hours, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and concentrated in vacuo to give the crude ester (0.41 g). ES-MS (M+H)⁺=234.

5

To a chilled solution of this residue in dichloromethane (4 mL) was added neat TFA (4 mL). After 1.5 hr at room temperature, the reaction was concentrated in vacuo and dried under high vac to give 2-(3-cyanophenoxy)acetic acid a white solid (0.3 g). ES-MS(M+H)⁺=178.

10

B. Preparation of 4-[2-(3-cyanophenoxy)acetylamino]benzoic acid

To a chilled solution of crude 2-(3-cyanophenoxy)acetic acid (0.3 g) in DMF (5 mL) and DIEA (0.785 mL) was added methyl 4-aminobenzoate (0.25 g, 1.65 mmol) and BOP (0.80 g, 1.8 mmol). The reaction mixture was stirred at room temperature for 6 hours, diluted with ethyl acetate, washed with 5% NaHCO₃, 1N HCl, and brine, dried over sodium sulfate and concentrated in vacuo to give the crude amide (0.65 g). ES-MS (M+H)⁺=311.

20

To a suspension of this residue in methanol (8 mL) and acetonitrile (9 mL) was added 1N LiOH (1.5 mL). After 1 day of stirring at room temperature, the reaction was acidified with 1N HCl (4 mL) and extracted into ethyl acetate, washed with water and brine, dried over sodium sulfate, concentrated in vacuo, and purified by silica gel chromatography (MeOH/CH₂Cl₂) to give 4-[2-(3-cyanophenoxy)acetylamino]benzoic acid (0.17 g, 38% yield from 3-cyanophenol, part A). ES-MS (M+H)⁺=297.

C. Preparation of 4-[2-(3-amidinophenoxy)acetylamino]benzoic acid

30


A solution of 4-[2-(3-cyanophenoxy)acetylamino]benzoic acid (0.17 g, 0.57 mmol) and hydroxylamine.HCl (80 mg, 1.15 mmol) in dry ethanol (4 mL) and DIEA (0.3 mL, 1.72 mmol) was stirred at 60°C for 3.5 hours. The reaction was concentrated in vacuo and redissolved in glacial acetic acid (1.5 mL) and acetic anhydride (0.109 mL, 1.16 mmol). After 1 hour, methanol (1.5 mL) and 10% Pd/C (74 mg, 0.07 mmol) were added, and the reaction was hydrogenated under 1 atm H₂ for 17 hours. The reaction mixture was filtered, concentrated, and HPLC purified to

give 4-[2-(3-amidinophenoxy)-acetylamino]benzoic acid (0.12 g, 67%) as a white fluffy solid. ES-MS(M+H)⁺=314.

5 D. Preparation of 3-(*{N*-[4-(pyrrolidinylcarbonyl)phenyl]carbamoyl}methoxy)-benzenecarboxamidine


To a suspension of 4-[2-(3-amidinophenoxy)acetylamino]benzoic acid (15 mg, 0.048 mmol) and pyrrolidine (6 uL, 0.072 mmol) in DMF (0.1 mL) and DIEA (66 10 uL, 0.38 mmol) was added PyBOP (28 mg, 0.054 mmol). The resulting solution was stirred at room temperature for 2 hours, acidified and purified by HPLC to give 3-(*{N*-[4-(pyrrolidinylcarbonyl)phenyl]carbamoyl}methoxy)benzenecarboxamidine (16 mg, 73%) as a fluffy white solid. ES-MS(M+H)⁺=367.

15 Example 6 Preparation of 3-(*{N*-[4-(azaperhydroepinylcarbonyl)phenyl]carbamoyl}methoxy)benzenecarboxamidine




PyBOP coupling of 4-[2-(3-amidinophenoxy)acetylamino]benzoic acid in 20 Example 5C with hexamethyleneimine gave 3-(*{N*-[4-(azaperhydroepinylcarbonyl)phenyl]carbamoyl}methoxy)benzenecarboxamidine in moderate yield. ES-MS (M+H)⁺ = 395.

Example 7 Preparation of 3-(*{N*-[4-(piperidylcarbonyl)phenyl]carbamoyl}methoxy)-



PyBOP coupling of 4-[2-(3-amidinophenoxy)acetylamino]benzoic acid in Example 5C with piperidine gave 3-({N-[4-(piperidylcarbonyl)phenyl]carbamoyl}methoxy)-benzenecarboxamidine in moderate yield. ES-MS (M+H)⁺ = 381.

Example 8 Preparation of 3-({N-[4-(morpholin-4-ylcarbonyl)phenyl]carbamoyl}-methoxy)benzenecarboxamidine




10

PyBOP coupling of 4-[2-(3-amidinophenoxy)acetylamino]benzoic acid in Example 5C with morpholine gave 3-({N-[4-(morpholin-4-ylcarbonyl)phenyl]carbamoyl}-methoxy)benzenecarboxamidine in moderate yield. ES-MS (M+H)⁺ = 383.

15


Example 9 Preparation of 3-[(N- {4-[(4-methylpiperazinyl)carbonyl]phenyl}- carbamoyl)methoxy]benzenecarboxamidine



20

PyBOP coupling of 4-[2-(3-amidinophenoxy)acetylamino]benzoic acid in Example 5C with N-methylpiperazine gave 3-[(N- {4-[(4-methylpiperazinyl)carbonyl]phenyl}- carbamoyl)methoxy]benzenecarboxamidine in moderate yield. ES-MS (M+H)⁺ = 396.

Example 10 Preparation of tert-butyl 1-(*{*4-[2-(3-amidinophenoxy)acetyl amino]-phenyl}carbonyl)pyrrolidine-2-carboxylate




PyBOP coupling of 4-[2-(3-amidinophenoxy)acetyl amino]benzoic acid in

- 5 Example 5C with proline-t-butyl ester gave tert-butyl 1-(*{*4-[2-(3-amidinophenoxy)acetyl amino]-phenyl}carbonyl)pyrrolidine-2-carboxylate in moderate yield. ES-MS ($M+H$)⁺ = 467.

Example 11 Preparation of 1-(*{*4-[2-(3-amidino-phenoxy)-


- 10 acetyl amino]phenyl}carbonyl)pyrrolidine-2-carboxylic acid



TFA deprotection of tert-butyl 1-(*{*4-[2-(3-amidinophenoxy)acetyl amino]-phenyl}-carbonyl)pyrrolidine-2-carboxylate from Example 10 gave 1-(*{*4-[2-(3-amidino-phenoxy)-acetyl amino]phenyl}carbonyl)pyrrolidine-2-carboxylic acid. ES-MS ($M+H$)⁺=411.

Example 12 Preparation of 3-(*{*N-[4-(azetidinylcarbonyl)phenyl]carbamoyl}-methoxy)benzenecarboxamidine


20



PyBOP coupling of 4-[2-(3-amidinophenoxy)acetyl amino]benzoic acid in Example 5C with azetidine hydrochloride gave 3-({N-[4-(azetidinylcarbonyl)phenyl]carbamoyl} -methoxy)benzenecarboxamidine in moderate yield. ES-MS ($M+H$)⁺ = 353.

5

Example 13 Preparation of 3-({N-[4-(3-pyrrolinylcarbonyl)phenyl]carbamoyl} methoxy)-benzenecarboxamidine




10

PyBOP coupling of 4-[2-(3-amidinophenoxy)acetyl amino]benzoic acid in Example 5C with 3-pyrroline gave 3-({N-[4-(3-pyrrolinylcarbonyl)phenyl]carbamoyl} methoxy)-benzenecarboxamidine in moderate yield. ES-MS ($M+H$)⁺ = 365.

15

Example 14 Preparation of 3-(3-{[4-(pyrrolidinylcarbonyl)phenyl]amino}propoxy)benzenecarboxamidine



20 A. Preparation of (tert-butoxy)-N-[4-(pyrrolidinylcarbonyl)phenyl]carboxamide

To a mixture of Boc-4-aminobenzoic acid (0.71 g, 3.0 mmol) and pyrrolidine (0.275 mL, 3.3 mmol) in DMF (12 mL) and DIEA (1.6 mL) was added BOP (1.59 g, 3.6 mmol). The reaction was stirred at room temperature for 1.5 hours, diluted with ethyl acetate, washed with 5% NaHCO₃, 10% citric acid, and brine, dried over sodium sulfate, concentrated in vacuo and purified on silica gel

- 85 -

(5% MeOH/CH₂Cl₂) to give (tert-butoxy)-N-[4-(pyrrolidinylcarbonyl)phenyl]carboxamide (0.83 g, 95%) as a foam solid. ES-MS (M+H)⁺=291.

5 B. Preparation of 3-(3-bromopropoxy)benzenecarbonitrile

To a chilled suspension of 1,3-dibromopropane (0.51 mL, 5.0mmol) and cesium carbonate (0.98 g, 3 mmol) in dry DMF (4 mL) was added solid 3-cyanophenol (0.12 g, 1.0 mmol) in portions. After 1 hour at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, concentrated in vacuo, and purified on silica gel (CH₂Cl₂) to give 3-(3-bromopropoxy)benzene-carbonitrile as an oil (0.18 g, 61%). ES-MS (M+H)⁺=240,242 (Br).

15 C. Preparation of (tert-butoxy)-N-[3-(3-cyanophenoxy)propyl]-N-[4-(pyrrolidinylcarbonyl)phenyl]carboxamide

To a chilled suspension of (tert-butoxy)-N-[4-(pyrrolidinylcarbonyl)phenyl]carboxamide (73 mg, 0.25 mmol) and cesium carbonate (0.207g, 0.635 mmol) in DMF (2 mL) was added a solution of 3-(3-bromopropoxy)benzenecarbonitrile (67 mg, 0.28 mmol) in DMF (1 mL). The reaction was stirred at room temperature for 3 days, with some heating to 40°C and another addition of bromide (17 mg, 0.069 mmol). The reaction was then diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, concentrated in vacuo, and purified on silica gel to give (tert-butoxy)-N-[3-(3-cyanophenoxy)propyl]-N-[4-(pyrrolidinylcarbonyl)phenyl]carboxamide (99 mg, 82%). ES-MS (M+H)⁺=450.

D. Preparation of 3-(3-{[4-(pyrrolidinylcarbonyl)phenyl]amino}propoxy)-benzenecarboxamidine

30 A solution of (tert-butoxy)-N-[3-(3-cyanophenoxy)propyl]-N-[4-(pyrrolidinyl-carbonyl)phenyl]carboxamide (46 mg, 0.10 mmol) and hydroxylamine.HCl (14 mg, 0.20 mmol) in dry ethanol (1.5 mL) and DIEA (0.050 mL) was stirred at 55°C for 6 hours. The reaction was concentrated in vacuo and redissolved in glacial acetic acid (1.5 mL) and acetic anhydride (0.019 mL, 0.2 mmol). After 40 min, methanol (1 mL) and 10% Pd/C (13 mg, 0.012 mmol) were


- 86 -

added, and the reaction was hydrogenated under 1 atm H₂ for 5 hours. The reaction mixture was then filtered and concentrated in vacuo to give 3-(3-((tert-butoxy)-N-[4-(pyrrolidinylcarbonyl)phenyl]carbonylamino)propoxy)-benzenecarboxamidine, which was treated with neat TFA (1 mL) on ice for 40 minutes, concentrated and

- 5 HPLC purified to give 3-(3-{{[4-(pyrrolidinylcarbonyl)phenyl]amino}-propoxy)benzenecarboxamidine (37 mg, 95%) as a white fluffy solid.
ES-MS(M+H)⁺=367.

Example 15 Preparation of 3-(3-{N-[4-

- 10 (pyrrolidinylcarbonyl)phenyl]acetylaminio}-propoxy)benzenecarboxamidine




To a solution of 3-(3-{{[4-

- 15 (pyrrolidinylcarbonyl)phenyl]amino}propoxy)benzene-carboxamidine (7 mg, 0.019 mmol) in glacial acetic acid (0.2 mL) was added acetic anhydride (6 uL, 0.059 mmol). After 3 hours, the reaction was diluted with 0.1% TFA and HPLC purified to give 3-(3-{N-[4-(pyrrolidinylcarbonyl)phenyl]acetylaminio}-propoxy)benzenecarboxamidine (5 mg, 63%). ES-MS(M+H)⁺=409.

20

Example 16 Preparation of 3-(3-{2,2,2-trifluoro-N-[4-(pyrrolidinylcarbonyl)phenyl]acetylaminio}propoxy)-benzenecarboxamidine


25



3-(3-{2,2,2-trifluoro-N-[4-(pyrrolidinylcarbonyl)phenyl]acetyl amino}propoxy)-benzenecarboxamidine was synthesized in a similar manner as in Example 15. ES-MS(M+H)⁺=446.

5 Example 17 Preparation of 3-(2-{{[4-

(pyrrolidinylcarbonyl)phenyl]amino}ethoxy)benzenecarboxamidine




3-(2-{{[4-(pyrrolidinylcarbonyl)phenyl]amino}ethoxy)benzenecarboxamidine was synthesized in a similar manner to 3-(3-{[4-(pyrrolidinylcarbonyl)phenyl]amino}-propoxy)benzenecarboxamidine (Example 14). ES-MS(M+H)⁺=353.

10 Example 18 Preparation of 3-(2-{{N-[4-(pyrrolidinyl-


carbonyl)phenyl]acetyl amino}ethoxy)benzenecarboxamidine

15



Acetylation of 3-(2-{{[4-(pyrrolidinylcarbonyl)phenyl]amino}ethoxy)benzenecarboxamidine (Example 13) with acetic anhydride gave 3-(2-{{N-[4-(pyrrolidinylcarbonyl)phenyl]acetyl amino}ethoxy)benzenecarboxamidine. ES-MS(M+H)⁺=395.

20 Example 19 Preparation of 4-hydroxy-3-({N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl}methoxy)-benzenecarboxamidine



A. Preparation of 2-[3-cyano-6-(phenylmethoxy)phenoxy]acetic acid

5

To a suspension of 3-hydroxy-4-(phenylmethoxy)benzenecarbonitrile (0.228 g, 1.01 mmol) and cesium carbonate (0.82 g, 2.5 mmol) in dry DMF (1.5 mL) was added methyl bromoacetate (0.1 mL, 1.05 mmol). The reaction was stirred at room temperature for 1 hour, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and concentrated in vacuo to give methyl 2-[3-cyano-6-(phenylmethoxy)-phenoxy]acetate (0.29 g, 95%). ES-MS(M+H)⁺=298.

10 This residue was dissolved in methanol (2 mL) and 1N LiOH (0.72 mL) and stirred for 3 hours at room temperature. Concentration yielded 2-[3-cyano-6-(phenylmethoxy)phenoxy]acetic acid (0.218 g, 99%) as an off-white solid. ES-
15 MS(M+H)⁺=284.

B. Preparation of N-[4-(2-{[(tert-butyl)amino]sulfonyl}phenyl)phenyl]-2-[3-cyano-6-(phenylmethoxy)phenoxy]acetamide

20 To a solution of 2-[3-cyano-6-(phenylmethoxy)phenoxy]acetic acid (59 mg, 0.208 mmol) and {[2-(4-aminophenyl)phenyl]sulfonyl}(tert-butyl)amine (61 mg, 0.2 mmol) (Example XX) in DMF (1 mL) and DIEA (0.10 mL, 0.6 mmol) was added BOP (97 mg, 0.219 mmol). The reaction was stirred at room temperature for 23 hours, diluted with ethyl acetate, washed with 5% NaHCO₃, 1N HCl and brine, 25 dried over sodium sulfate, concentrated in vacuo and purified on silica gel (10% EtOAc/CH₂Cl₂) to give N-[4-(2-{[(tert-butyl)amino]sulfonyl}phenyl)phenyl]-2-[3-cyano-6-(phenylmethoxy)phenoxy]-acetamide (77 mg, 68%). ES-
MS(M+Na)⁺=592.


30 C. Preparation of 3-(N-[4-(2-{[(tert-butyl)amino]sulfonyl}phenyl)phenyl]-carbamoyl)methoxy)-4-hydroxybenzenecarboxamidine

A solution of N-[4-(2-{{(tert-butyl)amino}sulfonyl}phenyl)phenyl]-2-[3-cyano-6-(phenylmethoxy)phenoxy]acetamide (43 mg, 0.076 mmol) and hydroxylamine.HCl (11 mg, 0.158 mmol) in dry ethanol (1.5 mL) and DIEA (0.04 mL) was stirred at 65°C for 25 hours. The reaction was concentrated in vacuo and redissolved in glacial acetic acid (0.8 mL) and acetic anhydride (9 uL, 0.095 mmol). After 1 hour, methanol (1 mL) and 10% Pd/C (18 mg, 0.017 mmol) were added, and the reaction was hydrogenated under 1 atm H₂ for 4 hours. The reaction mixture was then filtered, concentrated in vacuo and HPLC purified to give 3-(N-[4-(2-{{(tert-butyl)amino}sulfonyl}phenyl)phenyl]carbamoyl)-4-hydroxybenzenecarboxamidine (12 mg, 32%) as a white fluffy solid.
ES-MS(M+H)⁺=497.

D. Preparation of 4-hydroxy-3-(N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl)-methoxybenzenecarboxamidine
15

A solution of 3-(N-[4-(2-{{(tert-butyl)amino}sulfonyl}phenyl)phenyl]carbamoyl)methoxy)-4-hydroxybenzenecarboxamidine (10 mg, 0.02 mmol) in neat TFA (0.3 mL) was stirred on an ice bath for 2 hours. In order to avoid production 20 of cyclized by-product, the solution was immediately diluted with cold 0.1% TFA and HPLC purified to give 4-hydroxy-3-(N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl)methoxy)-benzenecarboxamidine (6 mg, 68%).
ES-MS(M+H)⁺=441.

25 Example 20 Preparation of 4-hydroxy-3-(N-[4-(3-pyrrolinylcarbonyl)phenyl]carbamoyl)methoxy)-benzenecarboxamidine



30

A. Preparation of phenylmethyl 4-aminobenzoate

To a chilled suspension of Boc 4-aminobenzoic acid (0.356 g, 1.5 mmol) and cesium carbonate (0.532 g, 1.61 mmol) in dry DMF (4 mL) was added benzyl bromide (0.18 mL, 1.55 mmol). The reaction was stirred at room temperature for 5 2.5 hours, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and concentrated in vacuo to give phenylmethyl 4-[(tert-butoxy)carbonylamino]benzoate (0.45 g, 92%) as a white solid. ES-MS(M+Na)⁺=350.

10 To a chilled solution of this solid (0.29 g, 0.89 mmol) in dichloromethane (5 mL) was added neat TFA (4 mL). After stirring on an ice bath for 1 hour, the reaction was concentrated in vacuo, azeotroped with hexane and dried under high vac to give phenylmethyl 4-aminobenzoate (0.29 g, 99%) as a tan solid. ES-MS(M+H)⁺=228.

15 B. Preparation of phenylmethyl 4-{2-[3-cyano-6-(phenylmethoxy)phenoxy]-acetylamino}benzoate

20 To a chilled solution of phenylmethyl 4-aminobenzoate (0.19 g, 0.58 mmol) in dichloromethane (5 mL) and TEA (0.24 mL) was added chloroacetylchloride (50 uL, 0.63 mmol). The reaction was stirred cold for 2.5 hours, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and concentrated in vacuo to give phenylmethyl 4-(2-chloroacetylamino)benzoate (0.17 g). ES-MS(M+H)⁺=204,206 (Cl)

25 To a chilled solution of phenylmethyl 4-(2-chloroacetylamino)benzoate (0.17 g, 0.56 mmol) and 3-hydroxy-4-(phenylmethoxy)benzenecarbonitrile (0.12 g, 0.54 mmol) in DMF (2.5 mL) was added cesium carbonate (0.55 g, 1.69 mmol). After 16 hours at room temperature, the reaction was diluted with ethyl acetate, 30 washed with water and brine, dried over sodium sulfate, concentrated in vacuo and purified on silica gel (3% MeOH/CH₂Cl₂) to give phenylmethyl 4-{2-[3-cyano-6-(phenylmethoxy)phenoxy]-acetylamino}benzoate (0.26 g, 91%). ES-MS(M+H)⁺=493.

35 C. Preparation of 4-[2-(3-amidino-6-hydroxyphenoxy)acetylamino]benzoic acid

- 91 -


A solution of phenylmethyl 4-{2-[3-cyano-6-(phenylmethoxy)phenoxy]-acetylamino}benzoate (0.26 g, 0.52 mmol) and hydroxylamine.HCl (74 mg, 1.06 mmol) in dry ethanol (4 mL) and DIEA (0.27 mL) was stirred at 60°C for 48 hours. The reaction was concentrated in vacuo and redissolved in glacial acetic acid (4 mL) and acetic anhydride (74 uL, 0.78 mmol). After 1.5 hours, methanol (5 mL) and 10% Pd/C (0.13 g, 0.125 mmol) were added, and the reaction was hydrogenated under 1 atm H₂ for 4 hours. The reaction mixture was then filtered, concentrated in vacuo and HPLC purified to give 4-[2-(3-amidino-6-hydroxyphenoxy)acetylamino]benzoic acid (0.10 g, 61%) as a white fluffy solid.

10 ES-MS(M+H)⁺=330.

D. Preparation of 4-hydroxy-3-(N-[4-(3-pyrrolinylcarbonyl)phenyl]carbamoyl)-methoxy)-benzenecarboxamidine

15 To a chilled suspension of 4-[2-(3-amidino-6-hydroxyphenoxy)acetylamino]-benzoic acid (30 mg, 0.09 mmol) and pyrroline (12 uL, 0.16 mmol) in DMF (0.25 mL) and DIEA (0.13 mL, 0.75 mmol) was added PyBOP (57 mg, 0.11 mmol). After 2.5 hours at room temperature, the reaction was diluted with 0.1% TFA and HPLC purified to give 4-hydroxy-3-(N-[4-(3-pyrrolinylcarbonyl)phenyl]carbamoyl)-methoxy)-benzenecarboxamidine (11 mg, 31%) as a white fluffy solid. ES-MS(M+H)⁺=381.


25 Example 21 Preparation of 4-hydroxy-3-(N-[4-(pyrrolidinylcarbonyl)-phenyl]carbamoyl)methoxy)benzenecarboxamidine



30 PyBOP coupling of 4-[2-(3-amidino-6-hydroxyphenoxy)acetylamino]-benzoic acid (Example 20-D) with pyrrolidine gave 4-hydroxy-3-(N-[4-

(pyrrolidinylcarbonyl)-phenyl]carbamoyl}methoxy)benzenecarboxamidine . ES-MS(M+H)⁺=383.

Example 22 Preparation of 4-hydroxy-3-({N-[4-
5 (pyrrolidinylsulfonyl)phenyl]carbamoyl}methoxy)-
benzenecarboxamidine



10

A. Preparation of 4-nitro-1-(pyrrolidinylsulfonyl)benzene

To a chilled solution of pyrrolidine (46 uL, 0.55 mmol) in dichloromethane (2.5 mL) and DIEA (0.17 mL, 1.0 mmol) was added 4-nitrobenzenesulfonyl chloride (0.11 g, 0.5 mmol) portionwise as a solid. After 1.5 hours at room temperature, the reaction was diluted with ethyl acetate, washed with 1N HCl and brine, dried over sodium sulfate and concentrated in vacuo to give 4-nitro-1-(pyrrolidinylsulfonyl)benzene (0.11 g, 88%). ES-MS(M+H)⁺=257.

20 B. Preparation of 4-(pyrrolidinylsulfonyl)phenylamine


To a chilled suspension of 4-nitro-1-(pyrrolidinylsulfonyl)benzene (68 mg, 0.27 mmol) in glacial acetic acid (2 mL) was added zinc dust (0.175 g, 2.68 mmol). After stirring under argon at room temperature for 1.5 hours, the reaction was 25 filtered, concentrated in vacuo, dissolved in ethyl acetate, washed with 5% NaHCO₃ and brine, dried over sodium sulfate and concentrated in vacuo to give 4-(pyrrolidinylsulfonyl)-phenylamine (50 mg, 83%). ES-MS(M+H)⁺=227.

30 C. Preparation of 4-hydroxy-3-({N-[4-(pyrrolidinylsulfonyl)phenyl]carbamoyl}-methoxy)benzenecarboxamidine

- 93 -

Using a similar procedure to that described in Example 15-B,C, 4-(pyrrolidinyl-sulfonyl)-phenylamine was coupled with 2-[3-cyano-6-(phenylmethoxy)phenoxy]acetic acid , and the nitrile was converted to amidine to give 4-hydroxy-3-({N-[4-(pyrrolidinyl-sulfonyl)phenyl]carbamoyl}methoxy)-benzenecarboxamidine. ES-MS(M+H)⁺=419.

Example 23 Preparation of 2-(5-amino-2-hydroxyphenoxy)-N-[4-(pyrrolidinylcarbonyl)phenyl]-acetamide



10 A. Preparation of 2-[5-nitro-2-(phenylmethoxy)phenoxy]acetic acid

Using a similar procedure to that described in Example 19-A, 2-[5-nitro-2-(phenylmethoxy)phenoxy]acetic acid was synthesized from 5-nitro-2-(phenylmethoxy)-phenol. ES-MS(M+H)⁺=304.

15 B. Preparation of 2-[5-nitro-2-(phenylmethoxy)phenoxy]-N-[4-(pyrrolidinylcarbonyl)phenyl]acetamide

To a chilled solution of 2-[5-nitro-2-(phenylmethoxy)phenoxy]acetic acid (0.216 g, 0.713 mmol) and 4-aminophenyl pyrrolidinyl ketone (0.7 mmol) (Example 10-A) in DMF (1.8 mL) and DIEA (0.73 mL) was added PyBOP (0.40 g, 0.77 mmol). After 1.5 hours at room temperature, the reaction was diluted with ethyl acetate, washed with 5% NaHCO₃, 1N HCl and brine, dried over sodium sulfate and concentrated in vacuo to give 2-[5-nitro-2-(phenylmethoxy)phenoxy]-N-[4-(pyrrolidinylcarbonyl)phenyl]acetamide (0.36 g, 99%). ES-MS(M+H)⁺=476.

C. Preparation of 2-(5-amino-2-hydroxyphenoxy)-N-[4-(pyrrolidinylcarbonyl)phenyl]acetamide


30 To a suspension of 2-[5-nitro-2-(phenylmethoxy)phenoxy]-N-[4-(pyrrolidinyl-carbonyl)phenyl]acetamide (34 mg, 0.072 mmol) in ethyl acetate (1.5 mL) and methanol (1 mL) under argon was added 10% Pd/C (15 mg, 0.014 mmol).

- 94 -


The reaction was hydrogenated at 1 atm H₂ for 4 hours, filtered, concentrated in vacuo and HPLC purified to give 2-(5-amino-2-hydroxyphenoxy)-N-[4-(pyrrolidinylcarbonyl)-phenyl]acetamide (11 mg, 44%). ES-MS(M+H)⁺=356.

Example 24 Preparation of 3-(phenyl{N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl}methoxy)benzenecarboxamidine

5




A. Preparation of



10 Using a similar procedure to that described in Example 1-A, the titled compound was synthesized using methyl α -bromophenyl acetate instead of t-butyl bromoacetate. ES-MS(M+H)⁺ = 290.0.

B. Preparation of




15

To a stirring solution of {[2-(4-aminophenyl)phenyl]sulfonyl}(tert-butyl)amine (3.04g, 10mmol) in DCM(50ml) was added trimethylaluminum(15ml of 2M solution in hexane, 30mmol) dropwise. This was allowed to stir for 2.5hr before A (2.67g, 10mmol) was added. The reaction was allowed to stir overnight before being quenched with 1N HCl. The aqueous layer was washed twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered and concentrated. The residue was purified by Preparatory HPLC to yield product. ES-MS(M+Na)⁺⁼ 562.2.

C. Preparation of 3-(phenyl{N-[4-(2-sulfamoylphenyl)phenyl]carbamoyl}methoxy)benzenecarboxamidine

The titled compound was synthesized according to procedure in 1-F. ES-MS(M+H)⁺⁼501.1.


Example 25. Preparation of 3-(N-[4-(4,5-dichloroimidazolyl)phenyl]carbamoyl)phenylmethoxy)benzenecarboxamidine



Using a similar procedure to that described in Example 24, the titled compound was synthesized using 4-(4,5-dichloroimidazolyl)aniline instead of {[2-(4-aminophenyl)phenyl]sulfonyl}(tert-butyl)amine in A. ES-MS(M+H)⁺⁼463.0.

Example 26 Preparation of 3-{N-(2,5-dichloro-4-pyrrolylphenyl)carbamoyl}phenylmethoxy)benzenecarboxamidine


- 96 -



Using a similar procedure to that described in Example 24, the titled compound was synthesized using 2,5-dichloro-4-(pyrrol-yl)aniline instead of {[2-(4-aminophenyl)phenyl]sulfonyl}(tert-butyl)amine in A. ES-MS(M+H)⁺=462.0.

5

Example 27 Preparation of 3-[phenyl(N-{4-[3-(trifluoromethyl)pyrazolyl]phenyl}carbamoyl)methoxy]benzenecarbonamidine




10

15


Using a similar procedure to that described in Example 24, the titled compound was synthesized using 1-(4-aminophenyl)-3-trifluoromethylpyrazole instead of {[2-(4-aminophenyl)phenyl]sulfonyl}(tert-butyl)amine in A. ES-MS(M+H)⁺=480.1.

Example 28 Preparation of 3-(phenyl{N-[4-(pyrrolidinylcarbonyl)phenyl]carbamoyl)methoxy)benzenecarboxamidine




Using a similar procedure to that described in Example 5, the titled compound was synthesized using methyl α -bromophenylacetate instead of t-butyl bromoacetate in 5-A. ES-MS(M+H)⁺=443.1.

Example 29 Preparation of 2-(1-amino(7-isoquinolonyloxy))-2-phenyl-N-[4-(2-sulfamoylphenyl)phenyl]acetamide




A. Preparation of



10

Using a similar procedure to that described in Example 1-A, the titled compound was synthesized using 7-hydroxyisoquinoline instead of 3-cyanophenol.

15 B. Preparation of



Using a similar procedure to that described in Example 24-B, the titled compound was synthesized using 29-A instead of 24-A. ES-MS(M+H)⁺=566.2.

5 C. Preparation of 2-(1-amino(7-isoquinolyloxy))-2-phenyl-N-[4-(2-sulfamoylphenyl)phenyl]acetamide

To a solution of 29-B(137.5 mg, 0.243 mmol) in acetone (2 mL) at room temperature, m-chloroperbenzoic acid (88 mg, ~57-86%, 0.292 mmol) was added.


10 The mixture was stirred at room temperature overnight. The solvent was removed in vacuo. The residue was partitioned between EtOAc and sat. NaHCO₃. The organic phase was separated, dried over Na₂SO₄, concentrated in vacuo to give a solid.

15 The solid was dissolved in anhydrous pyridine (3 mL). To the solution, toluenesulfonyl chloride (52.4 mg, 0.275 mmol) was added. It was stirred at room temperature for 5 min. The solvent was removed in vacuo to give an oil.

20 The oil was dissolved in ethanolamine (4 mL). The solution was stirred at room temperature for 3 hours. Water and EtOAc were added. The organic phase was separated. The aqueous phase was extracted with EtOAc twice. The combined organic phases were dried over Na₂SO₄, concentrated in vacuo to give an oil.


25 The oil was dissolved in TFA (10 mL). The solution was allowed to stand at room temperature overnight. TFA was removed in vacuo. The residue was purified by HPLC using a gradient of 5% CH₃CN in H₂O (containing 0.1% TFA) to 95% CH₃CN over 65 min. Fractions containing the product were pooled, and lyophilized to give the titled compound. ES-MS(M+H)⁺=581.3.

Example 30 Preparation 2-(1-amino(7-isoquinolyloxy))-2-phenyl-N-[4-(pyrrolidinylcarbonyl)phenyl]acetamide




5 The titled compound was synthesized Using a similar procedure to that described in Example 29. ES-MS(M+H)⁺=467.1.

Example 31 Preparation of 3-({N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]carbamoyl}phenylmethoxy)benzenecarboxamide



10

A. Preparation of {[2-(4-amino-3-fluorophenyl)phenyl]sulfonyl}(tert-butyl)amine



15

- 100 -

The titled compound was synthesized Using a similar procedure to that described in Example 1-D using 4-bromo-2-fluoroaniline instead of 4-bromoaniline.


C. Preparation of 3-({N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]carbamoyl}phenylmethoxy)benzenecarboxamidine

The titled compound was synthesized Using a similar procedure to that described in Example 24 using {[2-(4-amino-3-fluorophenyl)phenyl]sulfonyl}(tert-butyl)amine. ES-MS(M+H)⁺=519.1.


10

Example 32 Preparation of 3-({N-[2-bromo-4-(2-sulfamoylphenyl)phenyl]carbamoyl}phenylmethoxy)benzenecarboxamide

15



A. Preparation of {[2-(4-amino-3-bromophenyl)phenyl]sulfonyl}(tert-butyl)amine




20

The titled compound was synthesized Using a similar procedure to that described in Example 1-D using 2,4-bromoaniline instead of 4-bromoaniline.

B. Preparation of 3-(*{N*-[2-bromo-4-(2-sulfamoylphenyl)phenyl]carbamoyl}phenylmethoxy)benzenecarboxamidine

5 The titled compound was synthesized Using a similar procedure to that described in Example 24 using {[2-(4-amino-3-bromophenyl)phenyl]sulfonyl}(tert-butyl)amine. ES-MS(M+H)⁺=580.1.


Example 33 Preparation of 2-(1-amino(7-isoquinolyloxy))-N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]-2-phenylacetamide



10


The titled compound was synthesized Using a similar procedure to that described in Example 29. ES-MS(M+H)⁺= 543.1.

15 Example 34 Preparation of 2-(1-amino(7-isoquinolyloxy))-N-[2-bromo-4-(2-sulfamoylphenyl)phenyl]-2-phenylacetamide




20 The titled compound was synthesized Using a similar procedure to that described in Example 29. ES-MS(M+H)⁺=604.1.

Example 35 Preparation of 2-(1-amino(7-isoquinolyloxy))-N-[2-chloro-4-(2-sulfamoylphenyl)phenyl]-2-phenylacetamide



5

A. Preparation of {[2-(4-amino-3-chlorophenyl)phenyl]sulfonyl}(tert-butyl)amine



10


The titled compound was synthesized Using a similar procedure to that described in Example 1-D using 4-bromo-2-chloroaniline.

B. Preparation of 2-(1-amino(7-isoquinolyloxy))-N-[2-chloro-4-(2-sulfamoylphenyl)phenyl]-2-phenylacetamide

The titled compound was synthesized Using a similar procedure to that described in Example 29 using {[2-(4-amino-3-chlorophenyl)phenyl]sulfonyl}(tert-butyl)amine. ES-MS(M+H)+= 560.1.


20

Example 36 Preparation of 2-(1-amino(7-isoquinolyloxy))-2-(4-bromophenyl)-N-[4-(2-sulfamoylphenyl)phenyl]acetamide



5 The titled compound was synthesized Using a similar procedure to that
described in Example 29. ES-MS($\text{M}+\text{H}$) $= 604.1$.


Example 37 Preparation of 2-(1-amino(7-isoquinolyloxy))-2-(4-chlorophenyl)-N-[4-(2-sulfamoylphenyl)phenyl]acetamide



10


The titled compound was synthesized Using a similar procedure to that
described in Example 29. ES-MS($\text{M}+\text{H}$) $= 560.1$.

15 Example 38 Preparation of 2-(1-amino(7-isoquinolyloxy))-2-(2-chlorophenyl)-N-[4-(2-sulfamoylphenyl)phenyl]acetamide




The titled compound was synthesized using a similar procedure to that described in Example 29. ES-MS(M+H) $+=$ 560.1.

Example 39 Preparation of 3-(N-[2-bromo-4-(pyrrolidinylcarbonyl)phenyl]carbamoyl)phenylmethoxy)benzenecarboxamidine
5



The titled compound was synthesized Using a similar procedure to that described in Example 24. ES-MS(M+H) $+=$ 522.1.

10 Example 40 Preparation of 2-(1-amino(7-isoquinolyloxy))-N-[2-bromo-4-(pyrrolidinylcarbonyl)phenyl]-2-phenylacetamide



15 The titled compound was synthesized Using a similar procedure to that described in Example 29. ES-MS(M+H) $+=$ 546.1.

BIOLOGICAL ACTIVITY EXAMPLES

Evaluation of the compounds of this invention is guided by in vitro protease activity assays (see below) and in vivo studies to evaluate antithrombotic efficacy, 20 and effects on hemostasis and hematological parameters.

The compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from 0 to 100 μ M. In the assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate is added to a solution containing test compound and the enzyme of interest and the residual catalytic activity of that enzyme is determined spectrophotometrically. The IC₅₀ of a compound is determined from the substrate turnover. The IC₅₀ is the concentration of test compound giving 50% inhibition of the substrate turnover. The compounds of the present invention desirably have an IC₅₀ of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferred compounds have an IC₅₀ of about 100 nM or less in the factor Xa assay. The compounds of the present invention desirably have an IC₅₀ of less than 4.0 μ M in the prothrombinase assay, preferably less than 200 nM, and more preferred compounds have an IC₅₀ of about 10 nM or less in the prothrombinase assay. The compounds of the present invention desirably have an IC₅₀ of greater than 1.0 μ M in the thrombin assay, preferably greater than 10.0 μ M, and more preferred compounds have an IC₅₀ of greater than 100.0 μ M in the thrombin assay.

Amidolytic Assays for determining protease inhibition activity

The factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl. The rates of hydrolysis of the para-nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with inhibitor for 5 minutes at room temperature, and were determined using the Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroaniline.

The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method described by Sinha, U. *et al.*, Thromb. Res., 75, 427-436 (1994). Specifically, the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of preincubation (5 minutes) of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 µM) in 20 mM Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl, 5 mM CaCl₂ and 0.1% bovine serum albumin. Aliquots from the complex-inhibitor mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes. Eight different concentrations of inhibitor are assayed in duplicate. A standard curve of thrombin generation by an equivalent amount of untreated complex are used for determination of percent inhibition.

15 Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis

A rabbit deep vein thrombosis model as described by Hollenbach, S. *et al.*, Thromb. Haemost. 71, 357-362 (1994), is used to determine the in-vivo antithrombotic activity of the test compounds. Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail. A standardized protocol consists of insertion of a 20 thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A non-occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is used as a measure of the antithrombotic activity of the studied compounds. Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for 25 blood sampling prior to and during steady state infusion of test compound. Initiation of thrombus formation begins immediately after advancement of the cotton thread apparatus

into the central venous circulation. Test compounds are administered from time = 30 min to time = 150 min at which the experiment is terminated. The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are analyzed for changes in hematological and coagulation parameters.

5 Effects of Compounds in Rabbit Venous Thrombosis model

Administration of compounds in the rabbit venous thrombosis model demonstrates antithrombotic efficacy at the higher doses evaluated. There are no significant effects of the compound on the aPTT and PT prolongation with the highest dose (100 µg/kg + 2.57 µg/kg/min). Compounds have no significant effects on hematological parameters as compared to saline controls. All measurements are an average of all samples after steady state administration of vehicle or (D)-Arg-Gly-Arg-thiazole. Values are expressed as mean \pm SD.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize 15 the compounds of the present invention and practice the claimed methods.

WHAT IS CLAIMED IS:

1. A compound according to the formula:



wherein:

5

A is selected from:

- (a) $\text{C}_1\text{-C}_6\text{-alkyl};$
- (b) $\text{C}_3\text{-C}_8\text{-cycloalkyl};$
- (c) $-\text{NR}^2\text{R}^3, -\text{C}(=\text{NR}^2)\text{-NR}^2\text{R}^3, -\text{C}(=\text{NR}^2)\text{-R}^3, -\text{N}(\text{R}^3)\text{-C}(=\text{NR}^2)\text{-NR}^2\text{R}^3;$
- 10 (d) phenyl, which is independently substituted with 0-2 R^1 substituents;
- (e) naphthyl, which is independently substituted with 0-2 R^1 substituents;
- 15 (f) a 3-8 membered saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system may be substituted with 0-2 R^1 groups;
- (f) a aromatic or non-aromatic fused bicyclic heterocyclic ring system having from 8 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^1 substituents;

20 R^1 is selected from:

Halo, $-\text{C}_{1-4}\text{alkyl}$ substituted by up to 4 of the same or different halogen atoms selected independently from the group consisting of chlorine, bromine, iodine and fluorine atoms, $-\text{C}_{1-4}\text{alkyl}$, $-\text{C}_{1-4}\text{alkyl-phenyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{3-8}\text{cycloalkyl}$, $\text{C}_{0-4}\text{alkylC}_{3-8}\text{cycloalkyl}$, $-\text{CN}$, $-\text{NO}_2$, $- (\text{CH}_2)_m\text{NR}^2\text{R}^3$, $-\text{SO}_2\text{NR}^2\text{R}^3$, $-\text{SO}_2\text{R}^2$, CF_3 , $-(\text{CH}_2)_m\text{OR}^2$, $-\text{C}(=\text{O})\text{-N}(\text{R}^2)\text{R}^3$, $-\text{C}(=\text{NR}^2)\text{-NR}^2\text{R}^3$, $-\text{C}(=\text{NR}^2)\text{-R}^3$, $-\text{C}(=\text{O})\text{-OR}^2$, and saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member

selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂;

m is an integer of 0-2;

5 R² and R³ are each independently selected from the group consisting of:

H, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkylphenyl and C₀₋₄alkylnaphthyl, C₀₋₄alkylheterocyclic, wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, -CN, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -N(-C₁₋₄alkyl, -C₀₋₄alkyl), -NH₂, and -NO₂, or R² and R³ together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

15 Y is a member selected from the group consisting of:

a direct link; a bivalent C₁-C₄-alkyl group, a bivalent C₂-C₄-alkynyl group, a bivalent C₂-C₄-alkenyl group, -CH₂-, -C(=O)-, -C(=N-R⁴)-, -N(-R⁴)-, -N(-R⁴)-CH₂-, -CH₂-N(-R⁴)-, -C(=O)-N(-R⁴)-, -N(-R⁴)-C(=O)-, -SO₂-, -O-, -SO₂-N(-R⁴)- and -N(-R⁴)-SO₂-;

20 R⁴ is a member selected from the group consisting of:

H, -C₁₋₄-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, -C₀₋₄-alkyl-aryl; -C₀₋₄-alkyl-heterocycle; wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN, and -NO₂;

D is a direct link or is a member selected from the group consisting of:

- (a) phenyl substituted with 0-2 R^{1a} groups;
- (b) naphthyl substituted with 0-2 R^{1a} groups;

(c) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

R^{1a} is a member selected from the group consisting of:

5 Halo, $-C_{1-4}\text{alkyl}$, $-C_{1-4}\text{alkyl-phenyl}$, $C_{2-6}\text{alkenyl}$, $C_{2-6}\text{alkynyl}$, $C_{3-8}\text{cycloalkyl}$, $C_{0-4}\text{alkyl}C_{3-8}\text{cycloalkyl}$, $-\text{CN}$, $-\text{NO}_2$, $-(\text{CH}_2)_m\text{NR}^{2a}\text{R}^{3a}$, $-\text{SO}_2\text{NR}^{2a}\text{R}^{3a}$, $-\text{SO}_2\text{R}^{2a}$, CF_3 , $-(\text{CH}_2)_n\text{OR}^{2a}$, $-\text{C}(=\text{O})-\text{N}(\text{R}^{2a})\text{R}^{3a}$; $-\text{C}(=\text{NR}^{2a})-\text{NR}^{2a}\text{R}^{3a}$; $-\text{C}(=\text{NR}^{2a})-\text{R}^{3a}$; $-\text{C}(=\text{O})-\text{OR}^{2a}$, and saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein
10 from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, $-\text{CN}$, $-C_{1-4}\text{alkyl}$, $-C_{2-6}\text{alkenyl}$, $-C_{2-6}\text{alkynyl}$, $-C_{3-8}\text{cycloalkyl}$, $-C_{0-4}\text{alkyl}C_{3-8}\text{cycloalkyl}$, $-\text{N}(-C_{1-4}\text{alkyl}, -C_{0-4}\text{alkyl})$, $-\text{NH}_2$, and $-\text{NO}_2$;

n is an integer of 0-2;

15 R^{2a} and R^{3a} are each independently selected from the group consisting of:

 H, $C_{1-4}\text{alkyl}$, $C_{2-6}\text{alkenyl}$, $C_{2-6}\text{alkynyl}$, $C_{3-8}\text{cycloalkyl}$, $C_{0-4}\text{alkyl}C_{3-8}\text{cycloalkyl}$, $C_{0-4}\text{alkylphenyl}$ and $C_{0-4}\text{alkylnaphthyl}$, $C_{0-4}\text{alkylheterocycle}$, wherein from 1-4 hydrogen atoms on the ring atoms of the aryl moieties may be independently replaced with a member selected from the group consisting of halo, $-\text{CN}$, $-C_{1-4}\text{alkyl}$, $-C_{2-6}\text{alkenyl}$, $-C_{2-6}\text{alkynyl}$, $-C_{3-8}\text{cycloalkyl}$, $-C_{0-4}\text{alkyl}C_{3-8}\text{cycloalkyl}$, $-\text{N}(-C_{1-4}\text{alkyl}, -C_{0-4}\text{alkyl})$, $-\text{NH}_2$, and $-\text{NO}_2$; or R^{2a} and R^{3a} together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;
20

25 E is a member selected from the group consisting of:

$-\text{C}(=\text{O})-\text{N}(-\text{R}^5)-$, $-\text{N}(-\text{R}^5)-\text{C}(=\text{O})-$, $-\text{N}(-\text{R}^5)-$, $-\text{N}(-\text{R}^5)-(\text{CH})_{0-2}-$;

R^5 is a member selected from the group consisting of:

 H; $-C_{1-4}\text{-alkyl}$, $-C_{0-4}\text{-alkylaryl}$, $-C_{0-4}\text{-alkyl-heteroaryl}$, and
 $-C_{1-4}\text{-alkyl-C}(=\text{O})-\text{O}-C_{0-4}\text{-alkyl}$, $-C_{1-4}\text{-alkyl-C}(=\text{O})-\text{N}(-\text{R}^{2b}, -\text{R}^{3b})$;

R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H. -C₁₋₄-alkyl, -C₀₋₄-alkyl-aryl; -C₀₋₄-alkyl-heterocycle, and R^{2b} and R^{3b} together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted
5 with 0-2 R^{1c} groups;

R^{1c} is a member selected from the group consisting of:

Halo, -C₁₋₄-alkyl, -CN, -NO₂, -C(=O)-N(-R^{2c}, -R^{3c}), -C(=O)-OR^{2c}, -(CH₂)₀₋₂-N(-R^{2c}, -R^{3c}), -SO₂-N(-R^{2c}, -R^{3c}), -SO₂R^{2c}, -CF₃ and -(CH₂)₀₋₂-OR^{2c};

R^{2c} and R^{3c} are each independently a member selected from the group consisting of:

10 H, -C₁₋₄-alkyl, -C₀₋₄-alkyl-aryl, -C₀₋₄-alkyl-heterocyclic group;

G is -CR⁶R^{6a}-, -CR⁶R^{6a}-CR⁷R^{7a}-, -CR⁶R^{6a}-CR⁷R^{7a}-CR^{7b}R^{7c}-,

R⁶, R^{6a}, R⁷, R^{7a}, -R^{7b}, R^{7c} are each a member independently selected from the group consisting of:

(a) H, alkyl, -C₀₋₂-alkyl-aryl, -C₀₋₂-alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR⁹, -CN, -CF₃, -NO₂, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-O-R⁹, -C₀₋₂-alkyl-C(=O)-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-C(=O)-OR⁸ and C₀₋₂-alkyl-N(-R⁹, -R¹⁰);

(b) -C₀₋₂-alkyl-C(=O)-OR⁸, -C₀₋₂-alkyl-C(=O)-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-O-R⁹, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-O-R⁹, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-N(R⁹, R¹⁰), -C₀₋₂-alkyl-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-N(-R⁹)-C(=O)-R¹⁰, -C₀₋₂-alkyl-N(-R⁹)-C(=O)-O-R¹⁰, -C₀₋₂-alkyl-N(-R⁸)-C(=O)-N(-R⁹ -R¹⁰), -C₀₋₂-alkyl-N(-R⁹)-SO₂-R¹⁰, -C₀₋₂-alkyl-N(-R₈)-SO₂-N(R⁹, -R¹⁰), and a naturally occurring or synthetic amino acid side chains;

25 R⁸, R⁹ and R¹⁰ are each a member independently selected from the group consisting of:

H, -C₁₋₄-alkyl, a -C₀₋₄-alkyl-carbocyclic aryl, a -C₀₋₄-alkyl-heterocycle, and

R⁹ with R¹⁰, together with the N atom to which they are attached may each independently form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1d} groups;

5 R^{1d} is a member selected from the group consisting of:

halo, -C₁₋₄-alkyl, -CN, -NO₂, -C(=O)-N(-R^{2d}, -R^{3d}), -C(=O)-OR^{2d}, -(CH₂)_m-N(-R^{2d}, -R^{3d}); -SO₂-N(-R^{2d}, -R^{3d}); -SO₂R^{2d}; -CF₃ and -(CH₂)_m-OR^{2d};

R^{2d} and R^{3d} are each independently a member selected from the group consisting of:

H, -C₁₋₄-alkyl and -C₁₋₄-alkyl-aryl;

10 J is a member selected from the group consisting of:

-O-, -O-CH(R¹¹)-, -S-, -S-CH(R¹¹)-, -S(=O)-, -S(=O)₂-, -S(=O)-CH(R¹¹)-, -S(=O)₂-CH(R¹¹)-;

R¹¹ is a member selected from the group consisting of:

15 H, alkyl, -C₀₋₂-alkyl-aryl, -C₀₋₂-alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR⁹, -CN, -CF₃, -NO₂, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-O-R⁹, -C₀₋₂-alkyl-C(=O)-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-C(=O)-OR⁸ and C₀₋₂-alkyl-N(-R⁹, -R¹⁰);

K is a member selected from the group consisting of:

(a) phenyl, which is independently substituted with 0-2 R^{1e} groups;

20 (b) naphthyl, which is independently substituted with 0-2 R^{1e} groups;

(c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1e} groups;

25 R^{1e} is a member independently selected from the group consisting of:

halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkyl aryl, -C₀₋₂-CN, CF₃, -C₀₋₂-C(=O)-O-R^{2e}, -C₀₋₂-C(=O)-N(-R^{2e}, -R^{3e}), -C₀₋₂-NO₂, -C₀₋₂-N(-R^{2e}, -R^{3e}), -C₀₋₂-SO₂-N(-R^{2e}, -R^{3e}), -C₀₋₂-SO₂-R^{2e}, trihaloalkyl, -C₀₋₂-O-R^{2e}, C₀₋₂-N(-R^{2e})-CH₂-O-R^{2e}, 5 -O-CH₂-CH₂-O-R^{2e}, -O-CH₂-O-R^{2e}, -O-CH₂-C(=O)-O-R^{2e}, -C₀₋₂-N(-R^{2e})-CH₂CH₂-OR^{2e}, -C₀₋₂-N(-R^{2e})-C(=O)-R^{3e}, -C₀₋₂-N(-R^{2e})-SO₂-R^{3e}, -CH₂-N(-R^{2e})-C(=O)-R^{3e} and -CH₂-N(-R^{2e})-SO₂-R^{3e}.

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

10 H, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -C₁₋₄-alkyl-carbocyclic aryl; -C₁₋₄-alkyl-heterocycle, wherein from 1-4 hydrogen atoms on the ring atoms of aryl moieties may be independently replaced with a member selected from the group consisting of halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN and -NO₂, and R^{2e} and R^{3e} together with the N atom to which they are attached can form 5-8 membered heterocyclic ring (substituted with 0-2 R1) containing 1-4 heteroatoms selected from N, O and S which can be substituted with 0-2 R^{1g} groups;

15

R^{1g} is a member selected from the group consisting of:

20 Halo, -C₁₋₄-alkyl, a carbocyclic aryl group, a saturated, partially unsaturated or aromatic heterocyclic group, -CN, -C(=O)-N(R^{2g})R^{3g}, -C(=O)-OR^{2g}, -NO₂, -(CH₂)_m-NR^{2g}R^{3g}, -SO₂NR^{2g}R³, -SO₂R^{2g}, -CF₃, and -(CH₂)_mOR^{2g};

R^{2g} and R^{3g} are each independently selected from the group consisting of:

H; C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl;

25 L is selected from:

H, -CN, C(=O)NR¹²R¹³, (CH₂)₀₋₂NR¹²R¹³, C(=NR¹²)NR¹²R¹³, -NR¹²R¹³, OR¹², -NR¹²C(=NR¹²)NR¹²R¹³ and NR¹²C(=NR¹²)-R¹³;

R¹² and R¹³ are independently selected from:


hydrogen, -OR¹⁴, -NR¹⁴R¹⁵, C₁₋₄alkyl, C₀₋₄alkylaryl COOC₁₋₄alkyl, and COO-C₀₋₄alkylaryl, OCO-NR¹⁴R¹⁵; OCO-NR¹⁴R¹⁵(CH₂)₀₋₄ NR¹⁴R¹⁵, and R¹² and R¹³ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

R¹⁴ and R¹⁵ are independently selected from:

H, C₁₋₄alkyl; C₀₋₄alkylaryl; C₀₋₄alkylaryl, and R¹⁴ and R¹⁵ together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

2. A compound according to the formula:



wherein:

A is selected from:

- (a) -NR²R³, -C(=NR²)-NR²R³, -C(=NR²)-R³, -N(R³)-C(=NR²)-NR²R³
- (b) phenyl, which is independently substituted with 0-2 R¹ substituents;
- (C) a 3-7 membered saturated, partially unsaturated or aromatic heterocyclic ring systems containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system may be substituted with 0-2 R¹ groups;
- (d) a aromatic or non-aromatic fused bicyclic heterocyclic ring system having from 8 to 10 ring atoms, wherein 1-4 ring atoms of the ring

- 115 -

system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R¹ substituents;

R¹ is a member selected from the group consisting of:

halo; C₁₋₄-alkyl, a carbocyclic aryl group, a saturated, partially unsaturated or aromatic heterocyclic group containing 1-4 hetero atoms selected from the group consisting of O, N and S, -CN, -NO₂, -(CH₂)_mNR²R³, -SO₂NR²R³, -SO₂R², CF₃, -(CH₂)_mOR², -C(=O)-N(R²)R³; -C(=NR²)-NR²R³; -C(=NR²)-R³; -C(=O)-OR²;

R² and R³ are each independently selected from the group consisting of:

H; -C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl; or R² and R³ together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

m is an integer of 0-2;

Y is a member selected from the group consisting of:

a direct link; -CH₂-, -C(=O)-, -C(=N-R⁴)-, -N(-R⁴)-, -N(-R⁴)-CH₂-, -CH₂-N(-R⁴)-, -C(=O)-N(-R⁴)-, -N(-R⁴)-C(=O)-, -SO₂-, -O-, -SO₂-N(-R⁴)- and -N(-R⁴)-SO₂-;

R⁴ is a member selected from the group consisting of:

H, -C₁₋₄-alkyl and -C₀₋₄-alkyl-aryl;

D is a direct link or is a member selected from the group consisting of:

(a) phenyl substituted with 0-2 R^{1a} groups; and

(b) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

R^{1a} is a member selected from the group consisting of:

halo, -C₁₋₄-alkyl, -CN, -NO₂, -C(=O)-N(-R^{2a}, -R^{3a}), -C(=O)-OR^{2a}, -(CH₂)_m-N(-R^{2a}, -R^{3a}), -SO₂-N(-R^{2a}, -R^{3a}), -SO₂R^{2a}, -CF₃ and -(CH₂)_m-OR^{2a};

R^{2a} and R^{3a} are each independently a member selected from the group consisting of:

H; -C₁₋₄-alkyl and -C₁₋₄-alkylaryl;

5 E is a member selected from the group consisting of:

-C(=O)-N(-R⁵)- and -N(-R⁵)-C(=O)-;

R⁵ is a member selected from the group consisting of:

H; -C₁₋₄-alkyl; -C₀₋₄-alkylaryl; -C₀₋₄-alkyl-heteroaryl; -C₁₋₄-alkyl-C(=O)-OH and -C₁₋₄-alkyl-C(=O)-O-C₁₋₄-alkyl, -C₁₋₄-alkyl-C(=O)-N(-R^{2b}, -R^{3b});

10 R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H, -C₁₋₄-alkyl, -C₀₋₄-alkyl-aryl; -C₀₋₄-alkyl-heterocyclic group, and R^{2b} and R^{3b} together with the N atom to which they are attached can form a 5-8 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein the heterocyclic ring may be substituted with 0-2 R^{1c} groups;

15 R^{1c} is a member selected from the group consisting of:

Halo; -C₁₋₄-alkyl; -CN, -NO₂; -C(=O)-N(-R^{2c}, -R^{3c}); -C(=O)-OR^{2c}; -(CH₂)_m-N(-R^{2c}, -R^{3c}); -SO₂-N(-R^{2c}, -R^{3c}); -SO₂R^{2c}; -CF₃ and -(CH₂)_m-OR^{2c};

R^{2c} and R^{3c} are each independently a member selected from the group consisting of:

H; -C₁₋₄-alkyl and -C₁₋₄-alkyl-aryl;

20 G is -CR⁶R^{6a}-, -CR⁶R^{6a}-CR⁷R^{7a},

R⁶, R^{6a}, R⁷, R^{7a} are each a member independently selected from the group consisting of:

(a) H, alkyl, -C₀₋₂-alkyl-aryl, -C₀₋₂-alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR⁹, -CN, -CF₃, -NO₂, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-O-R⁹, -C₀₋₂-alkyl-C(=O)-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-C(=O)-OR⁸- and C₀₋₂-alkyl-N(-R⁹, -R¹⁰);

(b) $-C_{0.2}\text{-alkyl-C(=O)-OR}^8$, $-C_{0.2}\text{-alkyl-C(=O)-N(-R}^9\text{, -R}^{10}\text{)}$, $-C_{0.2}\text{-alkyl-O-R}^9$,
 $-C_{0.2}\text{-alkyl-O-C}_{2.4}\text{-alkyl-O-R}^9$, $-C_{0.2}\text{-alkyl-O-C}_{2.4}\text{-alkyl-N(R}^9\text{, R}^{10}\text{)}$, $-C_0\text{-}$
 $_2\text{-alkyl-N(-R}^9\text{, -R}^{10}\text{)}$, $-C_{0.2}\text{-alkyl-N(-R}^9\text{)-C(=O)-R}^{10}$, $-C_0\text{-}$
5 $_2\text{-alkyl-N(-R}^9\text{)-C(=O)-O-R}^{10}$, $-C_{0.2}\text{-alkyl-N(-R}^8\text{)-C(=O)-N(-R}^9\text{ -R}^{10}\text{)}$, $-C_0\text{-}$
 $_2\text{-alkyl-N(-R}^9\text{)-SO}_2\text{-R}^{10}$, $-C_{0.2}\text{-alkyl-N(-R}_8\text{)-SO}_2\text{-N(R}^9\text{, -R}^{10}\text{)}$, and a naturally
occurring or synthetic amino acid side chains;

R^8 , R^9 and R^{10} are each a member independently selected from the group consisting
of:

10 H, $-C_{1.4}\text{-alkyl}$, a $-C_{0.4}\text{-alkyl-carbocyclic aryl}$; a $-C_{0.4}\text{-alkyl-heterocycle}$; and
 R^9 with R^{10} , together with the N atom to which they are attached may each
independently form a 5-8 membered heterocyclic ring containing 1-4
heteroatoms selected from N, O and S, wherein the heterocyclic ring may be
substituted with 0-2 R^{1d} groups;

15 R^{1d} is a member selected from the group consisting of:

halo, $-C_{1.4}\text{-alkyl}$, $-CN$, $-NO_2$, $-C(=O)\text{-N(-R}^{2d}\text{, -R}^{3d}\text{)}$, $-C(=O)\text{-OR}^{2d}$,
 $-(CH_2)_m\text{-N(-R}^{2d}\text{, -R}^{3d}\text{)}$; $-SO_2\text{-N(-R}^{2d}\text{, -R}^{3d}\text{)}$; $-SO_2R^{2d}$; $-CF_3$ and $-(CH_2)_m\text{-OR}^{2d}$;

R^{2d} and R^{3d} are each independently a member selected from the group consisting of:

H, $-C_{1.4}\text{-alkyl}$ and $-C_{1.4}\text{-alkyl-aryl}$;

20 J is a member selected from the group consisting of:

$-O\text{-}$, $-O\text{-CH(R}^{11}\text{)}$;

R^{11} is a member selected from the group consisting of:

H; $-C_{1.4}\text{-alkyl}$ and $-C_{0.4}\text{-alkyl-carbocyclic aryl}$;

K is a member selected from the group consisting of:

25 (a) phenyl, which is independently substituted with 0-2 R^{1e} groups;
(b) naphthyl, which is independently substituted with 0-2 R^{1e} groups and

(c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1e} groups;

5 R^{1e} is a member independently selected from the group consisting of:

halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, C₀₋₄alkyl aryl; -C₀₋₂-CN; CF₃, -C₀₋₂-C(=O)-O-R^{2e}; -C₀₋₂-C(=O)-N(-R^{2e}, -R^{3e}); -C₀₋₂-NO₂; -C₀₋₂-N(-R^{2e}, -R^{3e}); -C₀₋₂-SO₂-N(-R^{2e}, -R^{3e}); -C₀₋₂-SO₂-R^{2e}; trihaloalkyl; -C₀₋₂-O-R^{2e}; C₀₋₂-N(-R^{2e})-CH₂-O-R^{2e}, -O-CH₂-CH₂-O-R^{2e} -O-CH₂-O-R^{2e}, -O-CH₂-C(=O)-O-R^{2e}; -C₀₋₂-N(-R^{2e})-CH₂CH₂-OR^{2e}; -C₀₋₂-N(-R^{2e})-C(=O)-R^{3e}; -C₀₋₂-N(-R^{2e})-SO₂-R^{3e}; -CH₂-N(-R^{2e})-C(=O)-R^{3e} and -CH₂-N(-R^{2e})-SO₂-R^{3e}.

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

H, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -C₁₋₄-alkyl-carbocyclic aryl; -C₁₋₄-alkyl-heterocyclic, wherein from 1-4 hydrogen atoms on the ring atoms of aryl moieties may be independently replaced with a member selected from the group consisting of halo, C₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, C₀₋₄alkylC₃₋₈cycloalkyl, -CN and -NO₂, and R^{2e} and R^{3e} together with the N atom to which they are attached can form 5-8 membered heterocyclic ring (substituted with 0-2 R1) containing 1-4 heteroatoms selected from N, O and S which can be substituted with 0-2 R^{1g} groups;

R^{1g} is a member selected from the group consisting of:

halo; -C₁₋₄-alkyl, a carbocyclic aryl group ; a saturated, partially unsaturated or aromatic heterocyclic group; -CN; -C(=O)-N(R^{2g})R^{3g}; -C(=O)-OR^{2g}; -NO₂; -(CH₂)_m-NR^{2g}R^{3g}; -SO₂NR^{2g}R³; -SO₂R^{2g}; -CF₃; and -(CH₂)_mOR^{2g};

R^{2g} and R^{3g} are each independently selected from the group consisting of:

H; C₁₋₄-alkyl and -C₀₋₄-alkyl-carbocyclic aryl;

L is selected from:

- 119 -

H, -CN, C(=O)NR¹²R¹³, (CH₂)_nNR¹²R¹³, C(=NR¹²)NR¹²R¹³, -NR¹²R¹³, OR¹², -NR¹²C(=NR¹²)NR¹²R¹³ and NR¹²C(=NR¹²)-R¹³;

R¹² and R¹³ are independently selected from:

hydrogen, -OR¹⁴, -NR¹⁴R¹⁵, C₁₋₄alkyl, C₀₋₄alkylaryl COOC₁₋₄alkyl, and
5 COO-C₀₋₄alkylaryl, OCO-NR¹⁴R¹⁵; OCO-NR¹⁴R¹⁵(CH₂)₀₋₄ NR¹⁴R¹⁵, and R¹²
and R¹³ together with the N atom to which they are attached can form a 5-8
membered heterocyclic ring containing 1-4 heteroatoms selected from N, O
and S, wherein the heterocyclic ring may be substituted with groups
consisting of halo, -C₁₋₄alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl,
10 -C₀₋₄alkylC₃₋₈cycloalkyl, -CN, -NO₂, and -COO-C₀₋₄alkyl;

R¹⁴ and R¹⁵ are independently selected from:

H, C₁₋₄alkyl; C₀₋₄alkylaryl; C₀₋₄alkylaryl, and R¹⁴ and R¹⁵ together with the N
atom to which they are attached can form a 5-8 membered heterocyclic ring
containing 1-4 heteroatoms selected from N, O and S, wherein the
15 heterocyclic ring may be substituted with groups consisting of halo, -C₁₋₄alkyl,
-C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, -C₀₋₄alkylC₃₋₈cycloalkyl, -CN,
-NO₂, and -COO-C₀₋₄alkyl;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug
derivatives thereof.

20

3. A compound according to the formula:

A-Y-D-E-G-J-Z-L

wherein:

25 A is selected from:

- (a) -NR²R³, -C(=NR²)-NR²R³, -C(=NR²)-R³, -N(R³)-C(=NR²)-NR²R³;
- (b) phenyl, which is independently substituted with 0-2 R¹ substituents;
- (c) a 3-7 membered saturated, partially unsaturated or aromatic
30 heterocyclic ring systems containing 1-4 heteroatoms selected from
N, O and S, wherein 0-2 ring atoms of the heterocyclic ring system
may be substituted with 0-2 R¹ groups;

R¹ is a member selected from the group consisting of:

halo; C₁₋₄-alkyl, -(CH₂)_mNR²R³, -SO₂NR²R³, -SO₂R², CF₃, -(CH₂)_mOR², -C(=O)-N(R²)R³, -C(=NR²)-NR²R³, -C(=NR²)-R³, -C(=O)-OR²;

R² and R³ are each independently selected from the group consisting of:

5 H; -C₁₋₄-alkyl, or R² and R³ together with the N atom to which they are attached can form a 5 to 8 membered heterocyclic ring system containing 1-4 hetero atoms selected from the group consisting of O, N and S;

m is an integer of 0-2;

Y is a member selected from the group consisting of:

10 a direct link, -CH₂-, -C(=O)-, -C(=N-R⁴)-, -N(-R⁴)-, -N(-R⁴)-CH₂-, and -SO₂-;

R⁴ is a member selected from the group consisting of:

H, -C₁₋₄-alkyl;

D is a direct link or is a member selected from the group consisting of:

15 (a) phenyl substituted with 0-2 R^{1a} groups; and
(b) a 5-6 membered aromatic or non-aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, wherein 0-2 ring atoms on the heterocyclic ring are substituted with 0-2 R^{1a} groups;

R^{1a} is a member selected from the group consisting of:

20 halo, -C₁₋₄-alkyl;

E is a member selected from the group consisting of:

-N(-R⁵)-C(=O)-;

R⁵ is a member selected from the group consisting of:

- 121 -

H; -C₁₋₄-alkyl, -C₀₋₄-alkylaryl, -C₀₋₄-alkyl-heteroaryl, -C₁₋₄-alkyl-C(=O)-OH and -C₁₋₄-alkyl-C(=O)-O-C₁₋₄-alkyl, -C₁₋₄-alkyl-C(=O)-N(-R^{2b}, -R^{3b});

R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H, -C₁₋₄-alkyl;

5 G is -CR⁶R^{6a}-, -CR⁶R^{6a}-CR⁷R^{7a}-,

R⁶, R^{6a}, R⁷, R^{7a} are each a member independently selected from the group consisting of:

10 H, alkyl, -C₀₋₂-alkyl-aryl, -C₀₋₂-alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo, OR⁹, -CN, -CF₃, -NO₂, -C₀₋₂-alkyl-O-C₂₋₄-alkyl-O-R⁹, -C₀₋₂-alkyl-C(=O)-N(-R⁹, -R¹⁰), -C₀₋₂-alkyl-C(=O)-OR⁸- and C₀₋₂-alkyl-N(-R⁹, -R¹⁰);

R⁸, R⁹ and R¹⁰ are each a member independently selected from the group consisting of:

15 H, -C₁₋₄-alkyl;

J is a member selected from the group consisting of:

-O-;

K is a member selected from the group consisting of:

(a) phenyl, which is independently substituted with 0-2 R^{1c} groups;

20 (b) naphthyl, which is independently substituted with 0-2 R^{1c} groups and

(c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R^{1c} groups;

25 R^{1c} is a member independently selected from the group consisting of:

- 122 -

halo, C_{1-4} alkyl, $-C_{0-2}N(-R^{2e}, -R^{3e})$, $-C_{0-2}O-R^{2e}$, $C_{0-2}N(-R^{2e})-CH_2-O-R^{2e}$,
 $-O-CH_2-CH_2-O-R^{2e}$, $-O-CH_2-O-R^{2e}$, $-O-CH_2-C(=O)-O-R^{2e}$,
 $-C_{0-2}N(-R^{2e})-CH_2CH_2-OR^{2e}$

R^{2e} and R^{3e} are each independently a member selected from the group consisting of:

5 H, C_{1-4} alkyl;

L is selected from:

$(CH_2)_{0-2}NR^{12}R^{13}$, $C(=NR^{12})NR^{12}R^{13}$, $-NR^{12}C(=NR^{12})NR^{12}R^{13}$;

R^{12} and R^{13} are independently selected from:

10 hydrogen, $-OR^{14}$, $-NR^{14}R^{15}$, C_{1-4} alkyl, $COOC_{1-4}$ alkyl, and $COO-C_{0-4}$ alkylaryl,
 $OCO-NR^{14}R^{15}$; $OCO-NR^{14}R^{15}(CH_2)_{0-4}NR^{14}R^{15}$, and R^{12} and R^{13} together with
the N atom to which they are attached can form a 5-8 membered heterocyclic
ring containing 1-4 heteroatoms selected from N, O and S, wherein the
heterocyclic ring may be substituted with groups consisting of halo, $-C_{1-4}$ alkyl,
 $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-C_{3-8}$ cycloalkyl, $-C_{0-4}$ alkyl C_{3-8} cycloalkyl, -
15 CN , $-NO_2$, and $-COO-C_{0-4}$ alkyl;

R^{14} and R^{15} are independently selected from:

H, C_{1-4} alkyl;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug
derivatives thereof.


20 4. A compound according to the formula::

A-Y-D-E-G-J-Z-L

Wherein:

A is a member selected from the group consisting of:

- 123 -




Y is a member selected from the group consisting of:

a direct link, -CH₂-; -C(=O)-; -NH-; -N(-CH₃)-; -N(-CH₃)-CH₂-; -C(=NH)- and -SO₂-

D is a member selected from the group consisting of:

5



E is a member selected from the group consisting of:

-N(-R⁵)-C(=O)-;

R⁵ is a member selected from the group consisting of:

10 H; -C₁₋₄-alkyl; -C₀₋₄-alkylaryl; -C₀₋₄-alkyl-heteroaryl; -C₁₋₄-alkyl-C(=O)-OH and -C₁₋₄-alkyl-C(=O)-O-C₁₋₄-alkyl, -C₁₋₄-alkyl-C(=O)-N(-R^{2b}, -R^{3b});

R^{2b} and R^{3b} are each a member independently selected from the group consisting of:

H, -C₁₋₄-alkyl;

G is -CR⁶R^{6a}-; -CR⁶R^{6a}-CR⁷R^{7a}-,


15 R⁶, R^{6a}, R⁷, R^{7a} are each a member independently selected from the group consisting of:

H, alkyl, -C₀₋₂-alkyl-aryl, -C₀₋₂-alkyl-heteroaryl, wherein 1-2 ring H atoms of aryl may be replaced with halo; -CN; -CF₃; -NO₂; -C₀₋₂-alkyl-C(=O)-NH₂; -C₀₋₂-alkyl-C(=O)-OH; and C₀₋₂-alkyl-NH₂; C₀₋₂-alkyl-OH; C₀₋₂-alkyl-OMe;

J is a member selected from the group consisting of:


5 -O-;

K and L taken together are a member selected from the group consisting of:




and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

5. A compound of claim 1 selected from the group consisting of:



5

wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:




Y is a member selected from the group consisting of:

a direct link, -CH₂-; -C(=O)-; -NH-; -N(-CH₃)-; -N(-CH₃)-CH₂-; -C(=NH)- and -SO₂-; and


R^{1a} is selected from the group consisting of:

-H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂; -C(=O)-O-Me.

5 6. A compound of claim 1 selected from the group consisting of:



wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:



Y is a member selected from the group consisting of:



- 130 -

a direct link, -CH₂-, -C(=O)-, -NH-, -N(-CH₃)-, -N(-CH₃)-CH₂-, -C(=NH)- and -SO₂-; and

R^{1a} is selected from the group consisting of:


5 -H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂; -C(=O)-O-Me.

7. A compound of claim 1 selected from the group consisting of:



10

wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:



Y is a member selected from the group consisting of:


- 132 -

a direct link, -CH₂-, -C(=O)-, -NH-, -N(-CH₃)-, -N(-CH₃)-CH₂-, -C(=NH)- and -SO₂-; and

R^{1a} is selected from the group consisting of:


5 -H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂; -C(=O)-O-Me.

8. A compound of claim 1 selected from the group consisting of:



10

wherein the A portion for each of the above formulae is independently a member selected from the group consisting of:



Y is a member selected from the group consisting of:


a direct link, -CH₂-, -C(=O)-, -NH-, -N(-CH₃)-, -N(-CH₃)-CH₂-, -C(=NH)- and -SO₂-; and

R^{1a} is selected from the group consisting of:


- 5 -H; -Cl; -F; -Br; -Me; -O-Me; -NO₂; -COOH; -CN; -C(=O)-NH₂; -C(=O)-O-Me.

9. A compound of claim 1 selected from the group consisting of:


10




- 15 wherein the D portion for each of the above formulae is independently a member selected from the group consisting of:



10. A compound of claim 1 selected from the group consisting of:




5 wherein the D portion for each of the above formulae is independently a member selected from the group consisting of:



- 136 -

11. A compound of claim 1 selected from the group consisting of:




5

wherein R^{1b} is each a member independently selected from the group consisting of:


H, Br, F, Cl, I, NH₂, OH, OMe, -CN, -CF₃, -NO₂, -CO₂H, CO₂Me.

10 12. A compound of claim 1 selected from the group consisting of:





wherein the Z-L portion for each of the above formulae is independently a member selected from the group consisting of:


15





13. A compound of claim 1 selected from the group consisting of:











14. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a compound of claim 1.

15. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising the step of administering to said mammal a therapeutically effective amount of a compound of claim 1.

5 16. The method of claim 15, wherein the condition is selected from the group consisting of: acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, 10 deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular 15 catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.

17. A method for inhibiting the coagulation of biological samples, comprising the step of administering a compound of claim 1.